var title_f15_9_15504="Fingertip avulsion repair";
var content_f15_9_15504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a fingertip avulsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    First, carefully approximate and suture the wound where it intersects with the nail folds and then suture the skin of the finger pad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Richard A Saladino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15504=[""].join("\n");
var outline_f15_9_15504=null;
var title_f15_9_15505="Mebeverine: International drug information";
var content_f15_9_15505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mebeverine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bevispas (ZA);",
"     </li>",
"     <li>",
"      Colese (AU);",
"     </li>",
"     <li>",
"      Colofac (AT, AU, GB, IE, ZA);",
"     </li>",
"     <li>",
"      Colopriv (FR);",
"     </li>",
"     <li>",
"      Colospa (IN);",
"     </li>",
"     <li>",
"      Duspatal (DE, IT, NL, PT);",
"     </li>",
"     <li>",
"      Duspatalin (AR, BE, CH, CZ, DK, ES, FR, HU, LU);",
"     </li>",
"     <li>",
"      Mebemerck (DE);",
"     </li>",
"     <li>",
"      Mebeverine EG (BE);",
"     </li>",
"     <li>",
"      Mebeverine Hydrochloride (GB);",
"     </li>",
"     <li>",
"      Rudakol (HR);",
"     </li>",
"     <li>",
"      Spasmonal (BE, LU);",
"     </li>",
"     <li>",
"      Spasmopriv (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Mebeverine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of irritable bowel syndrome",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 100-135 mg 3 times/day before meals or 200 mg 2 times/day (modified release capsule)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Granules: 135 mg/packet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Suspension: 10 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 100 mg, 135 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10410 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15505=[""].join("\n");
var outline_f15_9_15505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979430\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979423\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979425\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979428\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979424\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821090\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979427\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10410|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_9_15506="Patient information: Nocturnal (nighttime) leg cramps (The Basics)";
var content_f15_9_15506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17181\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/24/32142\">",
"         How to stretch the backs of your legs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/58/22434\">",
"         Patient information: Insomnia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/29/20946\">",
"         Patient information: Restless legs syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/16/2306\">",
"         Patient information: Insomnia (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nocturnal-nighttime-leg-cramps-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18244645\">",
"      <span class=\"h1\">",
"       What are nocturnal (nighttime) leg cramps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nighttime leg cramps cause pain and sudden muscle tightness in the legs, feet, or both. The cramps can wake you up from sleep. They can last for many minutes or just a few seconds.",
"     </p>",
"     <p>",
"      Nighttime leg cramps are common in both adults and children. But as people get older, they are more likely to get them. About half of people older than 50 get nighttime leg cramps.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18244660\">",
"      <span class=\"h1\">",
"       What causes nighttime leg cramps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most nighttime leg cramps do not have a cause that doctors can find. When doctors do find causes, the causes can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Having a leg or foot structure that is different from normal &ndash; For example, having flat feet or a knee that bends in the wrong direction",
"       </li>",
"       <li>",
"        Sitting in an awkward position or sitting too long in 1 position",
"       </li>",
"       <li>",
"        Standing or walking a lot on concrete floors",
"       </li>",
"       <li>",
"        Changes in your body&rsquo;s fluid balance &ndash; This can happen if you:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Take medicines called diuretics (also called &ldquo;water pills&rdquo;)",
"       </li>",
"       <li>",
"        Are on dialysis (a kind of treatment for kidney disease)",
"       </li>",
"       <li>",
"        Sweat too much",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Exercising",
"       </li>",
"       <li>",
"        Having certain conditions &ndash; For example, Parkinson disease, diabetes, or low thyroid",
"       </li>",
"       <li>",
"        Being pregnant &ndash; Some pregnant women do not have enough of the mineral magnesium in their blood. This can cause leg cramps.",
"       </li>",
"       <li>",
"        Taking certain medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18244675\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Things you can try include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Riding a stationary bike for a few minutes before bed &ndash; If you normally get little exercise, this might help.",
"       </li>",
"       <li>",
"        Doing stretching exercises (",
"        <a class=\"graphic graphic_picture graphicRef63450 \" href=\"UTD.htm?31/24/32142\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Wearing shoes with firm support, especially at the back of your foot around your heel",
"       </li>",
"       <li>",
"        Keeping bed covers loose at the foot of your bed and NOT tucked in",
"       </li>",
"       <li>",
"        Drinking plenty of water, especially if you take diuretics. (Do this only if your doctor or nurse has not told you to limit the amount of water you drink.)",
"       </li>",
"       <li>",
"        Limiting the amount of alcohol and caffeine you drink",
"       </li>",
"       <li>",
"        Staying cool when you exercise, and NOT exercising in very hot weather or hot rooms",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you get a cramp, slowly stretch the cramped muscle. To prevent more cramps, you can try:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Walking around or jiggling your leg or foot",
"       </li>",
"       <li>",
"        Lying down with your legs and feet up",
"       </li>",
"       <li>",
"        Taking a hot shower with water spraying on the cramp for 5 minutes, or taking a warm bath",
"       </li>",
"       <li>",
"        Rubbing the cramp with ice wrapped in a towel",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18244690\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See a doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You wake up several times a night with leg cramps",
"       </li>",
"       <li>",
"        Your cramps keep you from getting enough sleep",
"       </li>",
"       <li>",
"        Your cramps are very painful",
"       </li>",
"       <li>",
"        You have cramps in other parts of your body, such as your upper back or belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18244705\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse will talk with you about your symptoms and do an exam to find out what could be causing your nighttime leg cramps. Depending on your symptoms and exam, you might also need some blood tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18244720\">",
"      <span class=\"h1\">",
"       How are nighttime leg cramps treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment is different for everyone. Most people have to try a few different things before they find a treatment that helps them.",
"     </p>",
"     <p>",
"      Treatment options include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Making lifestyle changes &ndash; For example, exercising differently, doing stretching exercises, wearing shoes with good support, or drinking enough fluids",
"       </li>",
"       <li>",
"        Taking supplements &ndash; Supplements are pills, capsules, liquids, or tablets with minerals or vitamins your body needs. Tell your doctor or nurse about any minerals, vitamins, or herbal medicines you already take.",
"       </li>",
"       <li>",
"        Stopping any medicines you take that could cause cramps. But do not stop taking any medicine unless your doctor or nurse says it is OK. &nbsp;",
"       </li>",
"       <li>",
"        Medicines - Taking prescription medicines that improve sleep, relax muscles, calm overactive nerves, or help in other ways. Doctors and nurses prescribe medicines for nocturnal leg cramps only when other types of treatment do not work. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18244735\">",
"      <span class=\"h1\">",
"       What if my child gets nocturnal leg cramps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nocturnal leg cramps are common in children. Talk to your child&rsquo;s doctor or nurse if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has leg cramps often",
"       </li>",
"       <li>",
"        Cannot sleep well because of leg cramps",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Nocturnal leg cramps can run in families. Tell your doctor or nurse if someone else in your family also has nocturnal leg cramps.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18244773\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/29/20946?source=see_link\">",
"       Patient information: Restless legs syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=see_link\">",
"       Patient information: Insomnia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"       Patient information: Insomnia (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/9/15506?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17181 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15506=[""].join("\n");
var outline_f15_9_15506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244645\">",
"      What are nocturnal (nighttime) leg cramps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244660\">",
"      What causes nighttime leg cramps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244675\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244690\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244705\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244720\">",
"      How are nighttime leg cramps treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244735\">",
"      What if my child gets nocturnal leg cramps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18244773\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/24/32142\">",
"      How to stretch the backs of your legs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=related_link\">",
"      Patient information: Insomnia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/29/20946?source=related_link\">",
"      Patient information: Restless legs syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_9_15507="Foot taping PI";
var content_f15_9_15507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Foot taping for plantar fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This way of taping the foot sometimes helps with plantar fasciitis. Here are the steps involved, from left to right. 1) Wrap a strip of tape around the foot, at the level of the ball of the foot. 2) Wrap a second strip of tape around the heel, starting just below the pinky toe, around the sides of the heel, and back up to the first strip of tape. 3) Wrap a third strip of tape around the heel, starting just below the pinky toe, like you did in step 2. This time, circle the heel and wrap the tape in a criss-cross, so that it ends just below the big toe. 4) Repeat step 3. The tape does not need to align perfectly. The tape can stay in place for one week.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15507=[""].join("\n");
var outline_f15_9_15507=null;
var title_f15_9_15508="Plain radiographs - necrotizing enterocolitis in preterm infants";
var content_f15_9_15508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Radiograph of necrotizing enterocolitis in premature infants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal radiographs in premature infants with necrotizing enterocolitis. Left panel: There is marked abdominal distention due in part to dilated bowel loops, and bubbles of gas in the bowel wall due to extensive pneumatosis intestinalis (arrow). An orogastric tube is in place. Right panel: There is marked abdominal distention, pneumatosis intestinalis, and a suspicion of portal venous (arrow) and/or free intraperitoneal air.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15508=[""].join("\n");
var outline_f15_9_15508=null;
var title_f15_9_15509="Mucinous cystadenoma Light";
var content_f15_9_15509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic mucinous cystadenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic appearance of a mucinous pancreatic cystadenoma. Note cystic spaces lined with columnar goblet cells and stroma which has \"ovarian-like\" appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael L Steer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15509=[""].join("\n");
var outline_f15_9_15509=null;
var title_f15_9_15510="Neurovascular anatomy knee";
var content_f15_9_15510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Neurovascular anatomy of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The position of the popliteal artery and peroneal nerve make them vulnerable to injury when the knee is dislocated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15510=[""].join("\n");
var outline_f15_9_15510=null;
var title_f15_9_15511="Treatment of acute cholecystitis";
var content_f15_9_15511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute cholecystitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Salam F Zakko, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Charles M Vollmer, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15511/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/9/15511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholecystitis refers to a syndrome of right upper quadrant pain, fever, and leukocytosis associated with gallbladder inflammation, which is usually related to gallstone disease. Complications include the development of gangrene and gallbladder perforation, which can be life-threatening.",
"   </p>",
"   <p>",
"    The treatment of acute cholecystitis will be reviewed here (",
"    <a class=\"graphic graphic_algorithm graphicRef64526 \" href=\"UTD.htm?38/18/39214\">",
"     algorithm 1",
"    </a>",
"    ). The approach to patients with gallstones, and the clinical manifestations and diagnosis of acute cholecystitis and related conditions, such as acalculous and xanthogranulomatous cholecystitis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"     \"Uncomplicated gallstone disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=see_link\">",
"     \"Acalculous cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22534?source=see_link\">",
"     \"Xanthogranulomatous cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with acute cholecystitis should be admitted to the hospital. Patients have often been ill for days prior to seeking medical attention, making intravenous hydration and correction of any associated electrolyte disorders an important initial measure. Opioid analgesia may be required, although effective analgesia can usually be accomplished with an intramuscular injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (30 to 60 mg adjusted for age and renal function), which may also favorably alter the natural history of the disease (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Prevention'",
"    </a>",
"    below). Ketorolac and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    had similar efficacy in relieving biliary colic in a small randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients should be kept fasting, and those who are vomiting should have placement of a nasogastric tube, although this is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although acute cholecystitis is primarily an inflammatory process, secondary infection of the gallbladder can occur as a result of cystic duct obstruction and bile stasis. However, it is not clear that antibiotics are required for the treatment of uncomplicated acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/2\">",
"     2",
"    </a>",
"    ]. One study of 302 patients showed no difference in the development of empyema of the gallbladder or pericholecystic abscesses with the administration of antibiotics; there was, however, a lower rate of bacteremia and wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/3\">",
"     3",
"    </a>",
"    ]. This is likely due to the obstruction to bile flow that interferes with achieving adequate gallbladder bile concentrations of antibiotics. However, adequate serum and tissue concentrations of antibiotics protect against septic complications such as wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The guidelines of the Infectious Diseases Society of America (IDSA) recommend that antimicrobial therapy be instituted if infection is suspected on the basis of laboratory (more than 12,500 white cells per cubic millimeter) or clinical findings (temperature of more than 38.5&deg;C), and radiographic findings (eg, air in the gallbladder or gallbladder wall) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/2\">",
"     2",
"    </a>",
"    ]. Routine antibiotics are also recommended in older patients or those with diabetes or immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. When antibiotic therapy is initiated, the duration is tailored to clinical improvement. The need for prophylactic antibiotics at the time of surgery in the absence of clinical",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    of biliary infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=see_link&amp;anchor=H636461246#H636461246\">",
"     \"Open cholecystectomy\", section on 'Prophylactic antibiotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link&amp;anchor=H10#H10\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy should include activity against the most common pathogens. In a study of 467 patients, including a control group of 42 with normal biliary trees, positive bile cultures were found in 22 percent of patients with symptomatic gallstones and 46 percent of patients with acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/6\">",
"     6",
"    </a>",
"    ]. The most frequent isolates from the gallbladder or common bile duct were Escherichia coli (41 percent), Enterococcus (12 percent), Klebsiella (11 percent), and Enterobacter (9 percent). Empiric antibiotic therapy options and doses are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"     table 1",
"    </a>",
"    ). Antibiotic therapy should subsequently be tailored to culture and susceptibility results when available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841140036\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute cholecystitis, pain control can usually be achieved with nonsteroidal antiinflammatory drugs (NSAIDs) or opioids. Progression of pain during treatment for acute cholecystitis, despite adequate analgesia, is an indication of a clinical process of evolving severity worthy of re-evaluation.",
"   </p>",
"   <p>",
"    We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (30 to 60 mg adjusted for age and renal function given in a single intramuscular dose) for patients with biliary colic. Treatment usually relieves symptoms within 20 to 30 minutes. Opioids are appropriate therapy for patients who have contraindications to NSAIDs or who do not achieve adequate pain relief with an NSAID, which may be more common in patients with acute cholecystitis compared with uncomplicated gallstone disease.",
"   </p>",
"   <p>",
"    The role for NSAIDs in the treatment of biliary colic was demonstrated in a meta-analysis of 11 randomized trials with 1076 patients that compared NSAIDs with no treatment, placebo, or other treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/7\">",
"     7",
"    </a>",
"    ]. NSAIDs were more likely to control pain than placebo (relative risk [RR] 3.8; 95% confidence interval [CI] 1.7-8.6) or antispasmodics (RR 1.5; 95% CI 1.0-2.1). In addition, there was no difference in pain control between NSAIDs and opioids (RR 1.1; 95% CI 0.8-1.3). NSAIDs may also favorably alter the the progression of inflammation due to the role of prostaglandins in the development of acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opioids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , are an appropriate alternative for patients who cannot take NSAIDs or who fail to respond to an NSAID. It was traditionally thought that meperidine was the opioid of choice in patients with gallstone disease because it has less of an effect on sphincter of Oddi motility than morphine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. However, a systematic review found that all opioids increase sphincter of Oddi pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/11\">",
"     11",
"    </a>",
"    ]. There are insufficient data to suggest that morphine should be avoided. Morphine has an advantage that it requires less frequent dosing than meperidine, which has a shorter half-life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TIMING OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is consensus that incidentally discovered asymptomatic gallstones should not be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], once a patient develops symptoms or complications related to gallstones (such as biliary colic or acute cholecystitis), treatment to eliminate the gallstones should be recommended, because the likelihood of subsequent symptoms or complications is high. The National Cooperative Gallstone Study, a trial of nonsurgical treatment with chenodiol for biliary tract pain, demonstrated that the risk of recurrent symptoms was approximately 70 percent during the two years following initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of treatment and timing of definitive therapy for acute cholecystitis depends upon the severity of symptoms and the patient's overall risk of surgery. In severe cases, when gangrene or perforation are suspected, or if patients develop signs of instability (progressive fever, intractable pain) while on supportive therapy, intervention must be considered on an emergent basis to remove the offending inflamed, gangrenous, or perforated gallbladder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74614 \" href=\"UTD.htm?5/56/6019\">",
"     image 1",
"    </a>",
"    ). Often, cardiac arrhythmias are indicative of impending decompensation, which demands prompt intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=see_link&amp;anchor=H1324456987#H1324456987\">",
"     \"Overview of complications occurring in the post-anesthesia care unit\", section on 'Arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aim of definitive therapy is to eliminate the precipitating cause of acute cholecystitis (ie, gallstones in the case of calculous cholecystitis) to prevent recurrent attacks. A meta-analysis of 12 randomized trials concluded that early cholecystectomy (ranging from immediate cholecystectomy to cholecystectomy within seven days of symptoms) was the preferred approach [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/16\">",
"     16",
"    </a>",
"    ]. The benefit of prompt surgical intervention was also illustrated in a subsequent study of 29,818 Medicare patients with acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/17\">",
"     17",
"    </a>",
"    ]. Compared to patients who underwent cholecystectomy in the initial hospitalization, patients who were discharged without surgery were more likely to require readmission (38 versus 4 percent) and had higher mortality (hazard ratio 1.56, 95% CI 1.47-1.65) over the following two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Low-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical status scale established by the American Society of Anesthesiologists (ASA) (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"     table 2",
"    </a>",
"    ) is commonly used to determine the risk of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/18\">",
"     18",
"    </a>",
"    ]. Although previously considered to be at high risk, patients with diabetes mellitus who do not have substantial microvascular or macrovascular disease have an outcome after acute cholecystitis similar to the nondiabetic population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Immediate cholecystectomy is preferred for patients who are at low-risk (ASA classes I and II). Several studies have indicated that cholecystectomy performed for low surgical risk patients during the initial hospitalization can reduce morbidity and costs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In a randomized trial of 100 patients with acute cholecystitis, there were two deaths and four cases of peritonitis in patients who were awaiting delayed surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/22\">",
"     22",
"    </a>",
"    ]. Early surgery is also easier to perform as local inflammation increases 72 hours past the initial onset of symptoms making dissection less precise, increasing the severity of surgical complications, and open conversion more likely.",
"   </p>",
"   <p>",
"    Cholecystectomy can most often be accomplished laparoscopically. Laparoscopic cholecystectomy eliminates the need to cut the rectus abdominis muscle, reduces postoperative pain, and significantly shortens hospital length of stay and convalescence. However, conversion to open cholecystectomy should be performed if the surgeon fails to make adequate and safe progress in the dissection.",
"   </p>",
"   <p>",
"    Surgery for acute cholecystitis can be complicated by common bile duct injuries or excessive blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Injury and blood loss can be avoided by performing a subtotal cholecystectomy, leaving the dome of the gallbladder adherent to the liver fossa in situ, and achieving control of the cystic duct at the level of the neck of the gallbladder. Biliary leaks following this approach are possible, but generally can be managed conservatively. Overall, open cholecystectomy and laparoscopic cholecystectomy still have significant mortality rates (around 5 and 1 percent, respectively) and these rates are highest in the setting of acute cholecystitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6232?source=see_link\">",
"     \"Repair of common bile duct injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     High-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are in ASA classes III, IV, or V have a surgical mortality ranging from 5 to 27 percent, and are considered high-risk for cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/18\">",
"     18",
"    </a>",
"    ]. This category generally includes patients with severe chronic illnesses, such as cardiovascular or pulmonary disease, or advanced malignancy. In addition, otherwise low-risk patients who present with sepsis should also be considered high-risk until their physiologic profile can be improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5146500\">",
"    <span class=\"h3\">",
"     Gallbladder drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk patients, or patients who present late in the course of their disease process (beyond three to five days), who continue to have severe symptoms and show no appreciable improvement despite one to two days of medical management require further intervention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gallbladder drainage by percutaneous cholecystostomy in conjunction with antibiotics is the initial treatment of choice for such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]. The goal of cholecystostomy is to drain purulent material from the obstructed gallbladder. The technical success of percutaneous cholecystostomy ranges from 82 to 100 percent in various series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]. Tube decompression of the gallbladder allows for resolution of edema which often &ldquo;opens&rdquo; up the obstructed cystic duct. Success in resolving the acute cholecystitis is slightly less. Failure is usually related to ineffective drainage due to thick sludge or pus. We generally irrigate the gallbladder contents manually with normal saline through the catheter. If irrigation is ineffective, the percutaneous pigtail catheter can be replaced with a larger one to achieve more effective irrigation. Complications are infrequent but may include bleeding, catheter blockage and dislodgement, and failure to resolve the acute cholecystitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/27,29\">",
"       27,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endoscopic transpapillary gallbladder drainage has also been reported in patients with acute cholecystitis in whom percutaneous approaches are contraindicated or anatomically impossible [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. A limitation of the technique is that it can be technically challenging to place a guidewire and drainage tube into the gallbladder. In addition, this procedure carries all the inherent and occasionally serious complications of endoscopic retrograde cholangiography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"       \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5146535\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the cholecystitis has resolved, patients who are surgical candidates should undergo cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/32\">",
"     32",
"    </a>",
"    ]. Emergent operative approaches may be required, even in the face of high-risk physiology, as there are certain occasions when the aforementioned less-invasive techniques are not technically feasible. Furthermore, the risk of surgery may be less than the burden of continued systemic effects of cholecystitis on these already compromised patients.",
"   </p>",
"   <p>",
"    Surgery may also be required when the patient does not improve following percutaneous drainage, which suggests that the gallbladder has already progressed to gangrene. While total or subtotal cholecystectomy are both options, those patients who are particularly unstable will benefit from open cholecystostomy tube drainage achieved through a limited laparotomy. This can be performed at the bedside in the ICU setting if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5146528\">",
"    <span class=\"h3\">",
"     Nonsurgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who stabilize but continue to be at high risk for surgery can be considered for percutaneous gallstone extraction with or without mechanical lithotripsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall mortality of a single episode of acute cholecystitis is approximately 3 percent. However, the risk in a given patient depends upon the patient's health and surgical risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/27\">",
"     27",
"    </a>",
"    ]. The mortality is less than 1 percent in young, otherwise healthy patients, and approaches 10 percent in high-risk patients or in those in whom complications have developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to eliminating the cause of acute cholecystitis (usually gallstones), there is considerable interest in preventing the progression of biliary colic to acute cholecystitis. Increasing experience suggests that use of nonsteroidal antiinflammatory drugs (NSAIDs) can produce effective analgesia for biliary colic, and may favorably alter its natural history [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/9,33,34\">",
"     9,33,34",
"    </a>",
"    ]. The latter benefit may reflect the role of prostaglandins in the development of acute cholecystitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of NSAIDs was evaluated in a trial of 53 patients with cholelithiasis and biliary colic who were randomized to receive a single intramuscular injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    (75 mg) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/9\">",
"     9",
"    </a>",
"    ]. Treatment with diclofenac was significantly more effective in relieving pain and substantially reduced the rate of progression to acute cholecystitis (15 versus 42 percent). Another double-blind study of 37 patients who had 40 separate attacks of biliary colic demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    was also effective for relieving pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15511/abstract/35\">",
"     35",
"    </a>",
"    ]. We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (30 to 60 mg adjusted for age and renal function given in a single intramuscular dose) for patients who present to the emergency department with biliary colic. Treatment usually relieves symptoms within 20 to 30 minutes. Patients are then prescribed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    400 mg orally to be taken during subsequent attacks, until definitive treatment can be accomplished.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cholecystitis refers to a syndrome of right upper quadrant pain, fever, and leukocytosis associated with gallbladder inflammation, which is usually related to gallstone disease. Complications include the development of gangrene and gallbladder perforation, which can be life-threatening. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients diagnosed with acute cholecystitis require hospital admission for intravenous hydration, correction of electrolyte disorders, and pain control. Patients should be kept fasting and those who are vomiting may need placement of a nasogastric tube. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients requiring hospitalization for an episode of acute cholecystitis, we suggest empiric antibiotic therapy if infection is suspected on the basis of laboratory or clinical findings (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The selection of treatment and timing of definitive therapy for acute cholecystitis depends upon the severity of symptoms and the patient's overall risk of surgery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Timing of surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who are surgical candidates undergo cholecystectomy during their initial hospitalization (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Prompt surgical intervention decreases hospital readmission rates and mortality. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Low-risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-risk patients, or patients who present late in their disease course, who continue to have severe symptoms and show no appreciable improvement despite one to two days of medical management require further intervention with gallbladder drainage. (See",
"      <a class=\"local\" href=\"#H5146500\">",
"       'Gallbladder drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the cholecystitis has resolved, patients who are surgical candidates should undergo cholecystectomy. (See",
"      <a class=\"local\" href=\"#H5146535\">",
"       'Surgery'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Surgery may also be required when the patient does not improve following percutaneous drainage, which suggests that the gallbladder has already progressed to gangrene. While total or subtotal cholecystectomy are options, those patients who are particularly unstable will benefit from open cholecystostomy tube drainage achieved through a limited laparotomy. (See",
"      <a class=\"local\" href=\"#H5146535\">",
"       'Surgery'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Patients who stabilize but continue to be at high risk for surgery can be considered for percutaneous gallstone extraction with or without mechanical lithotripsy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/1\">",
"      Olsen JC, McGrath NA, Schwarz DG, et al. A double-blind randomized clinical trial evaluating the analgesic efficacy of ketorolac versus butorphanol for patients with suspected biliary colic in the emergency department. Acad Emerg Med 2008; 15:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/2\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/3\">",
"      Kune GA, Burdon JG. Are antibiotics necessary in acute cholecystitis? Med J Aust 1975; 2:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/4\">",
"      J&auml;rvinen H, Renkonen OV, Palmu A. Antibiotics in acute cholecystitis. Ann Clin Res 1978; 10:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/5\">",
"      Landau O, Kott I, Deutsch AA, et al. Multifactorial analysis of septic bile and septic complications in biliary surgery. World J Surg 1992; 16:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/6\">",
"      Csendes A, Burdiles P, Maluenda F, et al. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg 1996; 131:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/7\">",
"      Colli A, Conte D, Valle SD, et al. Meta-analysis: nonsteroidal anti-inflammatory drugs in biliary colic. Aliment Pharmacol Ther 2012; 35:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/8\">",
"      Henderson SO, Swadron S, Newton E. Comparison of intravenous ketorolac and meperidine in the treatment of biliary colic. J Emerg Med 2002; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/9\">",
"      Akriviadis EA, Hatzigavriel M, Kapnias D, et al. Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study. Gastroenterology 1997; 113:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/10\">",
"      Elta GH, Barnett JL. Meperidine need not be proscribed during sphincter of Oddi manometry. Gastrointest Endosc 1994; 40:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/11\">",
"      Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol 2001; 96:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/12\">",
"      Thune A, Baker RA, Saccone GT, et al. Differing effects of pethidine and morphine on human sphincter of Oddi motility. Br J Surg 1990; 77:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/13\">",
"      Ransohoff DF, Gracie WA. Treatment of gallstones. Ann Intern Med 1993; 119:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/14\">",
"      Friedman GD, Raviola CA, Fireman B. Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol 1989; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/15\">",
"      Thistle JL, Cleary PA, Lachin JM, et al. The natural history of cholelithiasis: the National Cooperative Gallstone Study. Ann Intern Med 1984; 101:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/16\">",
"      Papi C, Catarci M, D'Ambrosio L, et al. Timing of cholecystectomy for acute calculous cholecystitis: a meta-analysis. Am J Gastroenterol 2004; 99:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/17\">",
"      Riall TS, Zhang D, Townsend CM Jr, et al. Failure to perform cholecystectomy for acute cholecystitis in elderly patients is associated with increased morbidity, mortality, and cost. J Am Coll Surg 2010; 210:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/18\">",
"      Feigal DW, Blaisdell FW. The estimation of surgical risk. Med Clin North Am 1979; 63:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/19\">",
"      Ransohoff DF, Miller GL, Forsythe SB, Hermann RE. Outcome of acute cholecystitis in patients with diabetes mellitus. Ann Intern Med 1987; 106:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/20\">",
"      Norrby S, Herlin P, Holmin T, et al. Early or delayed cholecystectomy in acute cholecystitis? A clinical trial. Br J Surg 1983; 70:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/21\">",
"      Lahtinen J, Alhava EM, Aukee S. Acute cholecystitis treated by early and delayed surgery. A controlled clinical trial. Scand J Gastroenterol 1978; 13:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/22\">",
"      McArthur P, Cuschieri A, Sells RA, Shields R. Controlled clinical trial comparing early with interval cholecystectomy for acute cholecystitis. Br J Surg 1975; 62:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/23\">",
"      Gurusamy KS, Samraj K. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Cochrane Database Syst Rev 2006; :CD005440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/24\">",
"      Bernard HR, Hartman TW. Complications after laparoscopic cholecystectomy. Am J Surg 1993; 165:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/25\">",
"      National Institutes of Health Consensus Development Conference Statement on Gallstones and Laparoscopic Cholecystectomy. Am J Surg 1993; 165:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/26\">",
"      Melin MM, Sarr MG, Bender CE, van Heerden JA. Percutaneous cholecystostomy: a valuable technique in high-risk patients with presumed acute cholecystitis. Br J Surg 1995; 82:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/27\">",
"      Ito K, Fujita N, Noda Y, et al. Percutaneous cholecystostomy versus gallbladder aspiration for acute cholecystitis: a prospective randomized controlled trial. AJR Am J Roentgenol 2004; 183:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/28\">",
"      Davis CA, Landercasper J, Gundersen LH, Lambert PJ. Effective use of percutaneous cholecystostomy in high-risk surgical patients: techniques, tube management, and results. Arch Surg 1999; 134:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/29\">",
"      Byrne MF, Suhocki P, Mitchell RM, et al. Percutaneous cholecystostomy in patients with acute cholecystitis: experience of 45 patients at a US referral center. J Am Coll Surg 2003; 197:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/30\">",
"      Itoi T, Sofuni A, Itokawa F, et al. Endoscopic transpapillary gallbladder drainage in patients with acute cholecystitis in whom percutaneous transhepatic approach is contraindicated or anatomically impossible (with video). Gastrointest Endosc 2008; 68:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/31\">",
"      Kjaer DW, Kruse A, Funch-Jensen P. Endoscopic gallbladder drainage of patients with acute cholecystitis. Endoscopy 2007; 39:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/32\">",
"      Morse BC, Smith JB, Lawdahl RB, Roettger RH. Management of acute cholecystitis in critically ill patients: contemporary role for cholecystostomy and subsequent cholecystectomy. Am Surg 2010; 76:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/33\">",
"      Goldman G, Kahn PJ, Alon R, Wiznitzer T. Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor. Dig Dis Sci 1989; 34:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/34\">",
"      Thornell E, Nilsson B, Jansson R, Svanvik J. Effect of short-term indomethacin treatment on the clinical course of acute obstructive cholecystitis. Eur J Surg 1991; 157:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15511/abstract/35\">",
"      Thornell E, Jansson R, Svanvik J. Indomethacin intravenously--a new way for effective relief of biliary pain: a double-blind study in man. Surgery 1981; 90:468.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3684 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15511=[""].join("\n");
var outline_f15_9_15511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H841140036\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIMING OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Low-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      High-risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5146500\">",
"      - Gallbladder drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5146535\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5146528\">",
"      - Nonsurgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/3684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3684|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/18/39214\" title=\"algorithm 1\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3684|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/56/6019\" title=\"diagnostic image 1\">",
"      Ruptured gallbladder with biloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3684|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/21/7517\" title=\"table 1\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8733\" title=\"table 2\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=related_link\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=related_link\">",
"      Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33834?source=related_link\">",
"      Overview of complications occurring in the post-anesthesia care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6232?source=related_link\">",
"      Repair of common bile duct injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22534?source=related_link\">",
"      Xanthogranulomatous cholecystitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_9_15512="Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients";
var content_f15_9_15512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15512/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15512/contributors\">",
"     Matthew R Leibowitz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15512/contributors\">",
"     Judith S Currier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15512/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15512/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/9/15512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of disease due to non-tuberculous mycobacteria (NTM) in human immunodeficiency virus (HIV)-infected patients is caused by Mycobacterium avium complex (MAC), other NTM are important pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    .) Similar to MAC, the risk of disease from other NTM increases with progressive immunodeficiency, with the greatest risk experienced as the CD4 cell count decreases below 50",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the widespread use of combination antiretroviral therapy, HIV-infected patients developed disseminated disease caused by MAC; localized infection with MAC is now more common. By contrast, infection with other NTM can be disseminated or localized. The clinical manifestations vary among the NTM species, and the accurate diagnosis of true infection can be a challenge.",
"   </p>",
"   <p>",
"    The most commonly isolated NTM species, their clinical manifestations in patients with HIV infection, and recommendations for treatment will be reviewed here. The microbiology, pathogenesis, epidemiology, and clinical manifestations of NTM in patients without HIV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF DIAGNOSIS AND THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis and therapy of NTM in HIV-infected patients requires a thorough clinical assessment combined with culture data and appropriately directed empiric therapy.",
"   </p>",
"   <p>",
"    When NTM are isolated from a usually sterile site (eg, blood, bone marrow, lymph nodes, synovial fluid), the diagnosis of true disease is generally straightforward. However, when NTM are isolated from non-sterile sites, such as sputum or bronchoalveolar lavage (BAL) fluid, the diagnosis is less definitive, especially when the colony numbers are low or the isolate is present in only one cultured specimen. A diagnosis of infection then depends upon other clinical findings and the presence or absence of other pathogens. Organisms considered in other circumstances to be commensals can be opportunistic pathogens in patients with advanced HIV disease and immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case series from Spain identified 26 HIV-infected patients between 1998 and 2005 with NTM isolates from sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/2\">",
"     2",
"    </a>",
"    ]. Using clinical criteria to establish a diagnosis of colonization versus infection, the factors associated with disease were CD4 below 50",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    weight loss, hemoglobin below",
"    <span class=\"nowrap\">",
"     11g/dL,",
"    </span>",
"    duration of symptoms longer than a month, AFB smear positive sputum, and repeated positive NTM cultures.",
"   </p>",
"   <p>",
"    It is important to remember that experience with NTM other than MAC and M. kansasii is limited, and treatment decisions must be individualized. Further reports of non-tuberculosis mycobacterial infection with new NTM strains characterized by their unique 16S ribosomal RNA continue, adding to a growing list of rare pathogens for which diagnosis and treatment are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/3\">",
"     3",
"    </a>",
"    ]. In the Spanish study noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/2\">",
"     2",
"    </a>",
"    ], MAC and M. kansasii caused all disease, whereas other NTM were considered to be colonizers.",
"   </p>",
"   <p>",
"    The most recent recommendations of the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), updated in 2007, serve as a useful guide to the diagnosis and treatment of NTM disease in patients with or without HIV coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/4\">",
"     4",
"    </a>",
"    ]. Species identification is usually made through traditional biochemical testing of isolates; results often are not available for weeks. Newer molecular testing methods of clinical specimens, using direct amplification of nucleic acid probes (Gen-Probe and AccuProbe) to rapidly identify M. tuberculosis, M. kansasii, and MAC, can produce results in hours. However, false low-level positive tests for M. tuberculosis have been reported in specimens that later grew NTM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/5\">",
"     5",
"    </a>",
"    ], illustrating the need for caution when using these newer tests.",
"   </p>",
"   <p>",
"    Immune reconstitution inflammatory syndrome (IRIS), the paradoxical worsening of preexisting infectious processes after the start of combination antiretroviral therapy, has been frequently described among HIV-infected patients with known or previously undiagnosed mycobacterial infection, both tuberculous and non-tuberculous. The vast majority of non-tuberculous mycobacterial infections resulting in IRIS are due to MAC, but cases of IRIS related to infection with a variety of NTM other than MAC have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The immunobiology, pathogenesis, diagnosis, and treatment of IRIS related to mycobacterial infection are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM KANSASII",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. kansasii is the most frequently isolated NTM after MAC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The environmental source for the organism is not certain, but person-to-person transmission does not occur. Tap water is thought to be the most likely environmental source of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/4\">",
"     4",
"    </a>",
"    ]. Areas of greatest endemicity in the United States include Louisiana, Illinois, Texas, and Florida [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of isolation of this emerging pathogen is increasing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the period 1970 to 1990, M. kansasii became the most frequently isolated mycobacterial species overall in a Nebraska Veteran's Affairs hospital [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case series of M. kansasii infection have been reported from various regions worldwide, including Florida [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/12\">",
"       12",
"      </a>",
"      ] and Spain [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations are most similar to those of M. tuberculosis, although M. kansasii is a less virulent pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ]. Typical symptoms include fever, night sweats, weight loss, cough with sputum, dyspnea, and weakness. Pulmonary disease consists of infiltrates on chest radiograph with isolation of the organism from at least two respiratory specimens. The presentation of M. kansasii pulmonary infection usually does not differ in those who are HIV-infected or not, but the incidence of disseminated infection with this organism is higher in HIV-infected patients. Disseminated disease can be diagnosed by isolation of M. kansasii from sites other than the respiratory system, hilar lymph nodes, or skin.",
"   </p>",
"   <p>",
"    In the series of 46 patients from Florida, the median CD4 count in HIV-infected patients with M. kansasii infection was",
"    <span class=\"nowrap\">",
"     34/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/12\">",
"     12",
"    </a>",
"    ]. Forty-two patients (91 percent) had pulmonary infection; six of these cases also had disseminated disease. Only four (8 percent) of the patients had extrapulmonary disease without accompanying pulmonary involvement. The extrapulmonary sites included adenitis, bacteremia, osteomyelitis, and pericarditis.",
"   </p>",
"   <p>",
"    A population-based survey from California during 1992 to 1996 identified 270 infections with M. kansasii, and found that 69.3 percent of these cases were among HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with HIV infection were more likely to have mycobacteremia (9.6 percent versus 0 percent) and smear-positive respiratory specimens (41.7 percent versus 20.7 percent). Hospitalization for treatment was more common in the HIV-infected group.",
"   </p>",
"   <p>",
"    A case-control study from Spain compared the clinical presentations of M. kansasii and M. tuberculosis in HIV-infected patients and found that presenting symptoms and rates of dissemination were similar, but patients with M. kansasii presented with lower CD4 cell counts (median of 20 versus 90 for M. tuberculosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/15\">",
"     15",
"    </a>",
"    ]. The survival was worse for M. kansasii-infected patients, and central nervous system (CNS) disease was seen exclusively with M. tuberculosis infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common radiographic findings included interstitial and lobar infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/12\">",
"     12",
"    </a>",
"    ]. Cavitation, nodules, hilar adenopathy, and pleural effusion occurred less frequently. There is no clear predominance of upper or lower lobe involvement noted in the literature, and the radiographic appearance does not reliably distinguish M. kansasii from M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/16\">",
"     16",
"    </a>",
"    ]. Anecdotal reports of unusual presentations, such as cranial osteomyelitis, can be found [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of M. kansasii often begins with empiric therapy for M. tuberculosis after acid fast organisms are identified upon staining of respiratory specimens. After identification of M. kansasii is confirmed by biochemical testing or nucleic acid probe, therapy should continue with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (300 mg PO once daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (600 mg PO once daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PO once daily). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .) Although antimicrobial susceptibility testing may report resistance of the organism to isoniazid at 1",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    it is probably susceptible at the 5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    level, a concentration that is achievable in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/18\">",
"     18",
"    </a>",
"    ]. The standard duration of therapy is usually 12 months after negative sputum cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other antimicrobials that have proven successful in the management of M. kansasii infection include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , macrolides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ), and quinolones. In one retrospective study, treatment with a regimen including clarithromycin was associated with prolonged survival in both the pre- and post-combination antiretroviral therapy eras [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/19\">",
"     19",
"    </a>",
"    ]. Treatment conferred a clear survival benefit in various case series, suggesting that this organism should be considered a pathogen in all cases, unless there is absolutely no clinical evidence to support the diagnosis of M. kansasii disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series from California, among 127 patients with HIV infection and pulmonary M. kansasii infection, 53 percent died [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/21\">",
"     21",
"    </a>",
"    ]. Predictors of survival included higher CD4 cell count, antiretroviral therapy, negative smear microscopy, and adequate treatment for M. kansasii [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/21\">",
"     21",
"    </a>",
"    ]. In the New Orleans series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/19\">",
"     19",
"    </a>",
"    ], median survival in the combination ART era was 10.5 months when pulmonary disease was treated and 4.5 months when disease was not treated, indicating a poor prognosis in this severely immunocompromised population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM XENOPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. xenopi can be isolated from water, especially hot water sources, and is often considered a commensal. Reports of the endemicity of this organism vary. In a representative series of 28 patients from Toronto with both HIV and M. xenopi infection, 19 of 24 patients with measured CD4 counts had &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/22\">",
"     22",
"    </a>",
"    ]. Only seven patients (25 percent) were thought to have clinically significant disease, based upon the 1997 ATS guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/23\">",
"     23",
"    </a>",
"    ]. Three other patients had pulmonary disease with repeated isolation of M. xenopi, but other potential pathogens were also identified. In a second study from Buffalo, 23 of 35 patients (66 percent) with AIDS and pulmonary NTM other than MAC and M. kansasii had isolates of M. xenopi [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/24\">",
"     24",
"    </a>",
"    ]. Cavitary disease was rare, and interstitial and nodular lung disease were more common.",
"   </p>",
"   <p>",
"    The isolates were from lower respiratory specimens (sputum, BAL fluid, or lung biopsy) in 24 patients (86 percent) in the Ottawa study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/22\">",
"     22",
"    </a>",
"    ]. Three patients had bacteremia and a prolonged febrile illness with wasting, similar to disseminated MAC. Two had respiratory isolation of M. xenopi and Pneumocystis carinii simultaneously. Three patients had M. xenopi isolated from extrapulmonary sites: one each from inguinal lymph node, diarrheal stool, and urine.",
"   </p>",
"   <p>",
"    Four of the patients thought to have clinical disease were treated, and one appeared to respond [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/22\">",
"     22",
"    </a>",
"    ]. Sixteen patients died a median of six months after the isolation of M. xenopi, although none of the deaths were directly attributable to the organism. In a retrospective analysis, treated patients survived longer than untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/24\">",
"     24",
"    </a>",
"    ]. The distinction between colonization and disease may be difficult upon isolation of M. xenopi.",
"   </p>",
"   <p>",
"    Case reports describing vertebral osteomyelitis and discitis have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Few cases of M. xenopi spontaneous vertebral infection have been reported, but the disease course seems similar to that caused by M. tuberculosis.",
"   </p>",
"   <p>",
"    If M. xenopi is isolated as a single pathogen in a symptomatic HIV-infected patient, treatment may prolong survival. In vitro susceptibility of M. xenopi to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    is often reduced, but response to therapy does not always correlate with susceptibility data. Quinolones and macrolides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ) are likely to have good in vivo activity. The optimal number of antimicrobials and appropriate duration of therapy is not well defined, but a combination of isoniazid, rifampin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , ethambutol and clarithromycin has been recommended. A quinolone, preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , could be substituted for one of the antituberculous drugs. Optimal duration of therapy has not been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM HAEMOPHILUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. haemophilum disease most commonly presents in HIV-infected patients as painful, erythematous, ulcerating skin nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with tenosynovitis, arthritis, and osteomyelitis have also been reported. Similar to M. marinum and M. ulcerans, the organism grows best at 30 to 35 &ordm;C, explaining its tendency to cause skin and joint disease.",
"   </p>",
"   <p>",
"    M. haemophilum has been isolated from the blood, bone marrow, sputum, and BAL fluid of HIV-infected patients. Symptoms suggestive of disseminated disease frequently are present. Although cough also is a common symptom, this organism has not definitively been confirmed to be a pulmonary pathogen.",
"   </p>",
"   <p>",
"    M. haemophilum is more difficult than other NTM to isolate since it requires ferric ions (available in chocolate agar, supplemented media, and often in blood culture systems such as BACTEC or lysis centrifugation). The limited clinical experience in treating patients with M. haemophilum disease and the variable relationship between in vitro susceptibility data and in vivo activity also makes the choice of therapy problematic. Successful use of combinations of three or four drugs including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , rifamycins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM SIMIAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. simiae was originally isolated from rhesus monkeys and later from tap water. Infection with this organism may present in a fashion similar to disseminated MAC, with fever, night sweats, weight loss, and adenopathy, although its pathogenicity is not entirely clear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ]. Often thought to be a commensal in respiratory isolates, it has been described to cause pulmonary infection, disseminated disease with isolation from blood, osteomyelitis, and renal infection in AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. simiae often is resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and aminoglycosides in vitro.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    , ethambutol, quinolones, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    may be effective, but experience in treating this infection is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Overall prognosis was poor unless patients responded to both antiretroviral and antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM MALMOENSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. malmoense has been isolated from water and soil, and is a rarely isolated pathogen in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/4\">",
"     4",
"    </a>",
"    ]. The clinical presentation is similar to pulmonary infection with M. tuberculosis, but soft tissue infections, tenosynovitis, adenitis in children, and disseminated infection has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although in vitro data suggested resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , treatment with these agents for 18 to 24 months has been successful in HIV-negative patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    has also been shown to be active in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM FORTUITUM AND MYCOBACTERIUM CHELONAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;These rapidly growing mycobacteria are environmental organisms found worldwide and may grow in culture in less than one week. They are a cause of cutaneous infection, especially following trauma or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ]. In immunocompromised patients, reports of disease include disseminated disease with pustular and nodular cutaneous lesions, localized pulmonary disease with adenopathy, multifocal osteomyelitis, and lymphadenitis. A case series published in 2001 describes patients who predominantly presented with cervical lymphadenitis and fever and received other treatments before M. fortuitum infection was diagnosed. The morphologic appearance of the sometimes irregularly staining mycobacteria resulted in misdiagnosis of Nocardia in 7 of 11 patients, highlighting the difficulty in diagnosing this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimicrobials used with success include intravenous imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/4,34\">",
"     4,34",
"    </a>",
"    ]. The optimal duration of therapy is not defined, but treatment for a minimum of 6 to 12 months should be considered.",
"   </p>",
"   <p>",
"    A nosocomial pseudo-outbreak of M. fortuitum, linked to a contaminated ice machine on an HIV inpatient ward, was reported in Baltimore [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/35\">",
"     35",
"    </a>",
"    ]. Of 47 patients with at least one sputum specimen positive for M. fortuitum, only one had any signs of progressive pulmonary infection over six months of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM GENAVENSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated infection with an unidentified mycobacterium was reported in 18 patients in Switzerland in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/36\">",
"     36",
"    </a>",
"    ]. Acid fast bacilli were demonstrated in blood, lymph nodes, bone marrow, and intestinal biopsies, but no organisms were recovered in culture. Sequencing of 16S ribosomal RNA from tissue revealed a new mycobacterial species named M. genavense. Cases have since been reported worldwide, but almost exclusively in patients with AIDS and CD4 counts &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation is similar to disseminated MAC infection. M. genavense infection has been associated with massive adenopathy and organomegaly, especially splenomegaly, sometimes with splenic abscess. One case series describes the radiographic finding of small bowel thickening and hepatic nodules on an abdominal CT scan. Pulmonary infection has not been clearly demonstrated, but one patient had nodular infiltrates and a small upper lobe cavity on chest computed tomographic (CT) scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/37\">",
"     37",
"    </a>",
"    ]. In a comparison of 12 patients with HIV and disseminated M. genavense infection and 24 patients with HIV and disseminated MAC infection, Danish investigators found that MAC patients were less likely to have abdominal pain, but that otherwise the illness and survival times after diagnosis were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stool specimens tended to be smear-positive for M. genavense, but the organism was less likely to grow in culture (15 versus 71 percent for MAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/38\">",
"     38",
"    </a>",
"    ]. Bone marrow and liver biopsy specimens grew M. genavense more readily; the yield is maximized by using acidic liquid medium and additives and avoiding pretreatment. The organism was sensitive to rifamycins, quinolones, and macrolides, but resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    in vitro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM SZULGAI",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. szulgai can be found in water sources and is usually associated with pulmonary disease in a presentation similar to that of M. tuberculosis. Extrapulmonary presentations have been described in patients with HIV infection, and include cutaneous disease, osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/39\">",
"     39",
"    </a>",
"    ], and septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary disease has been successfully treated with various three- and four-drug regimens including macrolides and quinolones for a duration of 12 months with negative sputum cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/4\">",
"     4",
"    </a>",
"    ]. Extrapulmonary disease has been successfully treated with combinations including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. A case of pulmonary disease was reported with multidrug resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , ethambutol, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15512/abstract/41\">",
"     41",
"    </a>",
"    ]. After susceptibility results were available, the patient responded well to treatment with clarithromycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , ciprofloxacin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2821423\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the majority of disease due to non-tuberculous mycobacteria (NTM) in HIV-infected patients is caused by Mycobacterium avium complex, other NTM are important pathogens as well. The risk of disease from NTM increases with progressive immunodeficiency, with the greatest risk experienced as the CD4 cell count decreases below 50",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When NTM are isolated from a sterile site (eg, blood), the diagnosis of true disease is generally straightforward. However, when NTM are isolated from non-sterile sites, such as sputum, the diagnosis is less definitive. In the latter situation, a diagnosis of true NTM infection depends upon other clinical findings and the presence or absence of other potential pathogens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Principles of diagnosis and therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mycobacterium kansasii is the most frequently isolated NTM after MAC. The clinical manifestations are most similar to those of tuberculosis, although M. kansasii is a less virulent pathogen. Typical symptoms include fever, night sweats, weight loss, cough with sputum, dyspnea, and weakness. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mycobacterium kansasii'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. xenopi can cause fevers, wasting and pulmonary infiltrates, similar to disseminated Mycobacterium avium complex. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mycobacterium xenopi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. haemophilum disease most commonly presents as painful, erythematous, ulcerating skin nodules. Patients with tenosynovitis, arthritis, and osteomyelitis have also been reported. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mycobacterium haemophilum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rapidly growing mycobacteria, M. fortuitum and M. chelonae, can cause disseminated disease with pustular and nodular cutaneous lesions, localized pulmonary disease with adenopathy, multifocal osteomyelitis, and lymphadenitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mycobacterium fortuitum and mycobacterium chelonae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. genavense infection has been associated with massive adenopathy and organomegaly. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Mycobacterium genavense'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. szulgai has been associated with pulmonary disease, cutaneous lesions, osteomyelitis, and septic arthritis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mycobacterium szulgai'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/1\">",
"      Benator DA, Gordin FM. Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Semin Respir Infect 1996; 11:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/2\">",
"      Alvarez-Uria G, Falc&oacute; V, Mart&iacute;n-Casabona N, et al. Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization? Int J STD AIDS 2009; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/3\">",
"      Richter E, R&uuml;sch-Gerdes S, Niemann S, et al. Detection, identification, and treatment of a novel, non-cultivable Mycobacterium species in an HIV patient. AIDS 2000; 14:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/4\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/5\">",
"      Jorgensen JH, Salinas JR, Paxson R, et al. False-positive Gen-Probe direct Mycobacterium tuberculosis amplification test results for patients with pulmonary M. kansasii and M. avium infections. J Clin Microbiol 1999; 37:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/6\">",
"      Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/7\">",
"      Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/8\">",
"      Phillips DR, Krishnan H, Watson J. First UK report of successful treatment of Mycobacterium simiae and immune reconstitution inflammatory syndrome in an HIV-seropositive patient. Sex Transm Infect 2008; 84:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/9\">",
"      Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/10\">",
"      Good RC, Snider DE Jr. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/11\">",
"      Bittner MJ, Horowitz EA, Safranek TJ, Preheim LC. Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 1996; 22:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/12\">",
"      Campo RE, Campo CE. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/13\">",
"      Pintado V, G&oacute;mez-Mampaso E, Mart&iacute;n-D&aacute;vila P, et al. Mycobacterium kansasii infection in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1999; 18:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/14\">",
"      Bloch KC, Zwerling L, Pletcher MJ, et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/15\">",
"      Canueto-Quintero J, Caballero-Granado FJ, Herrero-Romero M, et al. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin Infect Dis 2003; 37:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/16\">",
"      Evans AJ, Crisp AJ, Hubbard RB, et al. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis. Thorax 1996; 51:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/17\">",
"      Capdevila O, Zurita A, Domingo E, et al. Multiple cranial osteolytic lesions due to Mycobacterium kansasii in a patient with AIDS. Scand J Infect Dis 1998; 30:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/18\">",
"      Lillo M, Orengo S, Cernoch P, Harris RL. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis 1990; 12:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/19\">",
"      Tompkins JC, Witzig RS. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects. Int J Tuberc Lung Dis 2007; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/20\">",
"      Marras TK, Daley CL. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr 2004; 36:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/21\">",
"      Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med 2004; 170:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/22\">",
"      el-Helou P, Rachlis A, Fong I, et al. Mycobacterium xenopi infection in patients with human immunodeficiency virus infection. Clin Infect Dis 1997; 25:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/23\">",
"      Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/24\">",
"      El-Solh AA, Nopper J, Abdul-Khoudoud MR, et al. Clinical and radiographic manifestations of uncommon pulmonary nontuberculous mycobacterial disease in AIDS patients. Chest 1998; 114:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/25\">",
"      Meybeck A, Fortin C, Abgrall S, et al. Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature. J Clin Microbiol 2005; 43:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/26\">",
"      Sobottke R, Zarghooni K, Seifert H, et al. Spondylodiscitis caused by Mycobacterium xenopi. Arch Orthop Trauma Surg 2008; 128:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/27\">",
"      Dever LL, Martin JW, Seaworth B, Jorgensen JH. Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS. Clin Infect Dis 1992; 14:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/28\">",
"      Straus WL, Ostroff SM, Jernigan DB, et al. Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients. Ann Intern Med 1994; 120:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/29\">",
"      Huminer D, Dux S, Samra Z, et al. Mycobacterium simiae infection in Israeli patients with AIDS. Clin Infect Dis 1993; 17:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/30\">",
"      Al-Abdely HM, Revankar SG, Graybill JR. Disseminated Mycobacterium simiae infection in patients with AIDS. J Infect 2000; 41:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/31\">",
"      Barzilai A, Rubinovich B, Blank-Porat D, et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. Scand J Infect Dis 1998; 30:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/32\">",
"      Fakih M, Chapalamadugu S, Ricart A, et al. Mycobacterium malmoense bacteremia in two AIDS patients. J Clin Microbiol 1996; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/33\">",
"      Smith MB, Schnadig VJ, Boyars MC, Woods GL. Clinical and pathologic features of Mycobacterium fortuitum infections. An emerging pathogen in patients with AIDS. Am J Clin Pathol 2001; 116:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/34\">",
"      Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/35\">",
"      Gebo KA, Srinivasan A, Perl TM, et al. Pseudo-outbreak of Mycobacterium fortuitum on a Human Immunodeficiency Virus Ward: transient respiratory tract colonization from a contaminated ice machine. Clin Infect Dis 2002; 35:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/36\">",
"      Hirschel B, Chang HR, Mach N, et al. Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/37\">",
"      Monill JM, Franquet T, Sambeat MA, et al. Mycobacterium genavense infection in AIDS: imaging findings in eight patients. Eur Radiol 2001; 11:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/38\">",
"      Thomsen VO, Dragsted UB, Bauer J, et al. Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol 1999; 37:3901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/39\">",
"      Tappe D, Langmann P, Zilly M, et al. Osteomyelitis and skin ulcers caused by Mycobacterium szulgai in an AIDS patient. Scand J Infect Dis 2004; 36:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/40\">",
"      Hakawi AM, Alrajhi AA. Septic arthritis due to Mycobacterium szulgai in a patient with human immunodeficiency virus: case report. Scand J Infect Dis 2005; 37:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15512/abstract/41\">",
"      Kang-Birken SL, Prichard JG. Mycobacterium szulgai in a patient with advanced acquired immunodeficiency syndrome: an unusual pathogen with unusual multidrug resistance. Pharmacotherapy 2006; 26:1646.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3705 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-2F8CF27215-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15512=[""].join("\n");
var outline_f15_9_15512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2821423\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF DIAGNOSIS AND THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MYCOBACTERIUM KANSASII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MYCOBACTERIUM XENOPI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MYCOBACTERIUM HAEMOPHILUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MYCOBACTERIUM SIMIAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MYCOBACTERIUM MALMOENSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MYCOBACTERIUM FORTUITUM AND MYCOBACTERIUM CHELONAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MYCOBACTERIUM GENAVENSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MYCOBACTERIUM SZULGAI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2821423\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=related_link\">",
"      Pathogenesis of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_9_15513="Initial management of cutaneous dermatomyositis";
var content_f15_9_15513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial management of cutaneous dermatomyositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15513/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15513/contributors\">",
"     Ruth Ann Vleugels, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15513/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15513/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15513/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/9/15513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13068987\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic dermatomyositis (DM) is an idiopathic inflammatory myopathy that most commonly presents with progressive, symmetric proximal muscle weakness and a group of characteristic cutaneous findings. The cutaneous manifestations of DM may also develop in the absence of detectable muscle disease, and can persist after the successful treatment of DM-associated myositis.",
"   </p>",
"   <p>",
"    Patients with DM often present with intensely pruritic areas of confluent, violaceous erythema on the scalp, face, upper trunk, and upper extremities. Pruritus can be disabling.",
"   </p>",
"   <p>",
"    Skin lesions of DM are often resistant to photoprotection and topical therapies alone, necessitating the initiation of antimalarial drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Patients who fail to respond to these interventions may require more aggressive immunosuppressive or immunomodulatory therapies.",
"   </p>",
"   <p>",
"    The initial management of the cutaneous manifestations of DM will be discussed here. The treatment of refractory DM, as well as the clinical manifestations, diagnosis, and management of the noncutaneous manifestations of DM and juvenile DM are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377280\">",
"    <span class=\"h1\">",
"     OVERVIEW OF CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin changes associated with DM include pathognomonic findings such as Gottron&rsquo;s papules (violaceous papules overlying interphalangeal and metacarpophalangeal joints) and Gottron&rsquo;s sign (macular violaceous erythema overlying the interphalangeal and metacarpophalangeal joints, elbows, or knees) (",
"    <a class=\"graphic graphic_picture graphicRef63383 graphicRef75246 graphicRef76704 \" href=\"UTD.htm?22/19/22842\">",
"     picture 1A-C",
"    </a>",
"    ). Violaceous erythema involving the periorbital skin (heliotrope eruption), scalp, V of the neck, shoulders, extensor surfaces of the upper extremities, upper chest, and upper back are additional characteristic findings in DM (",
"    <a class=\"graphic graphic_picture graphicRef56879 graphicRef68649 graphicRef54230 graphicRef77822 \" href=\"UTD.htm?28/25/29082\">",
"     picture 2A-D",
"    </a>",
"    ). Scale may or may not be present, but is typically prominent on the scalp, where it may be accompanied by diffuse alopecia (",
"    <a class=\"graphic graphic_picture graphicRef64903 \" href=\"UTD.htm?4/5/4181\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cutaneous lesions often exhibit hyperpigmentation in patients with dark skin (",
"    <a class=\"graphic graphic_picture graphicRef79924 \" href=\"UTD.htm?26/41/27284\">",
"     picture 4",
"    </a>",
"    ). Additional examples of cutaneous manifestations of DM include poikiloderma, calcinosis cutis, prominent periungual telangiectasias, and cuticular hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28087755\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life impairment related to skin disease is significant in DM, and has been shown to be greater in patients with DM than in patients with psoriasis or atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients frequently experience debilitating symptoms of severe pruritus or burning in affected areas, which can result in emotional distress and loss of sleep. Scalp pruritus may be particularly intense, and is the initial presenting symptom in DM in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101092388\">",
"    <span class=\"h2\">",
"     Disease course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous disease may persist for years. In one systematic review of primarily adult patients with cutaneous DM without myositis, the mean duration of skin disease was 4.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Long-term follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28087784\">",
"    <span class=\"h2\">",
"     Photosensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of cutaneous lesions in DM suggests that photosensitivity may contribute to the development of skin lesions. Similar to findings in lupus erythematosus, significantly reduced minimal erythema doses (MEDs, the minimal irradiation dose required to elicit cutaneous erythema) to UVB light have been detected in patients with DM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/3\">",
"     3",
"    </a>",
"    ]. In one study in which 19 patients with DM were irradiated with ultraviolet B (UVB) light, 9 (47 percent) exhibited reduced MEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although strict photoprotection is typically recommended for patients with DM, data are limited on the ability of ultraviolet light to directly induce the development of cutaneous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/4\">",
"     4",
"    </a>",
"    ]. Reproduction of lesions consistent with DM following solar-simulated radiation has been reported in at least one patient, and some patients with DM associate sun exposure with exacerbations of cutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, cases in which flares of internal manifestations of DM followed solar irradiation have been reported, similar to this more recognized phenomenon in lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13069036\">",
"     'Photoprotection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377365\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF CUTANEOUS DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with DM exhibit both cutaneous disease and muscle weakness (classic DM). However, a subset of patients develops characteristic skin findings of DM in the absence of muscle symptoms. This group is often referred to as clinically amyopathic DM (CADM), and contains both patients who lack clinical findings of myositis, but have evidence for myositis on laboratory, radiologic, or electrophysiologic studies (hypomyopathic DM) and patients in whom all signs of muscle involvement are absent (amyopathic DM) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/7\">",
"     7",
"    </a>",
"    ]. It is estimated that 9 to 13 percent of patients with CADM for more than six months eventually develop classic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Descriptions of the various presentations of cutaneous DM are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11395954\">",
"    <span class=\"h2\">",
"     Classic DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with DM present with simultaneous cutaneous and muscle involvement, evidenced by proximal muscle weakness and diagnostic testing that reveals the presence of myositis. However, the onset of cutaneous disease can precede the appearance of myositis by up to several months in 30 percent of patients with classic DM, and follows shortly after muscle involvement in 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"     2",
"    </a>",
"    ]. The term &ldquo;premyopathic DM&rdquo; is used to describe patients who have no clinical evidence for muscle disease, but have had cutaneous manifestations of DM for less than six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2068610\">",
"    <span class=\"h2\">",
"     Amyopathic DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, amyopathic DM was known as dermatomyositis sin&eacute; myositis. This variant is considered a distinct form of DM, rather than classic DM in which the onset of muscle involvement is delayed for a prolonged period. Amyopathic DM is diagnosed in patients who lack muscle weakness and have no laboratory or radiologic signs of myositis despite the presence of cutaneous findings consistent with DM for at least six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/7\">",
"     7",
"    </a>",
"    ]. The presence of drug-induced DM-like cutaneous changes, such as can occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , must be excluded.",
"   </p>",
"   <p>",
"    Approximately 10 to 20 percent of patients with DM seen in academic health centers have amyopathic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/8\">",
"     8",
"    </a>",
"    ]. The proportion may be higher among patients referred to dermatologists; in one dermatology referral center, approximately 40 percent of patients with DM had the amyopathic variant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2068617\">",
"    <span class=\"h2\">",
"     Hypomyopathic DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to amyopathic DM, hypomyopathic DM presents with cutaneous findings consistent with DM and the absence of clinically appreciable muscle weakness for at least six months after the appearance of skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast to amyopathic disease, subclinical evidence for myositis is evident through serologic testing for muscle enzymes, electromyography (EMG), muscle biopsy, or magnetic resonance imaging (MRI).",
"   </p>",
"   <p>",
"    Hypomyopathic DM is less common than amyopathic DM; among 281 patients with CADM in a systematic review, 37 (13 percent) had hypomyopathic disease, and 197 (70 percent) had amyopathic DM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2068718\">",
"    <span class=\"h2\">",
"     Postmyopathic DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In classic DM, cutaneous and muscle disease often have a discordant response to therapy. Postmyopathic DM describes the persistence of cutaneous symptoms following the resolution of muscle disease with immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11396053\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953899\">",
"    <span class=\"h2\">",
"     Indications for biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of cutaneous DM is suggested by the constellation of characteristic cutaneous findings, muscle weakness, and laboratory evidence of myositis. However, in patients who present with ambiguous cutaneous findings or cutaneous findings that are suggestive of DM in the absence of clinical signs of muscle disease, a skin biopsy should be performed.",
"   </p>",
"   <p>",
"    The histopathologic findings in DM are variable, but typically include an interface dermatitis characterized by vacuolization of basal keratinocytes, a lymphocytic infiltrate in the superficial dermis, and dermal mucin. The biopsy is useful for ruling out other disorders that may resemble DM, including seborrheic dermatitis, contact dermatitis, atopic dermatitis, polymorphous light eruption, and papulosquamous disorders such as lichen planus or psoriasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The greatest challenge in the diagnosis of DM involves the distinction between amyopathic DM and acute cutaneous lupus erythematosus (ACLE), which like DM, can present with photodistributed erythema and elevated antinuclear antibodies. The histopathologic findings of DM are often indistinguishable from ACLE. Of note, the intense pruritus often associated with DM usually does not occur in patients with ACLE. In addition, ACLE traditionally spares the nasolabial folds, while DM often involves these areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28087829\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient who presents with cutaneous features that are consistent with DM, investigation for concomitant muscle disease should be performed. Due to the possibility of subsequent development of muscle disease, patients without myositis should be evaluated with a muscle examination and serum creatinine kinase and aldolase levels every two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in classic DM, adults with CADM have an increased risk for pulmonary disease and internal malignancy. Thus, patients should be evaluated and followed for the presence of these disorders. In a systematic review that analyzed 291 adult patients with CADM, 36 (13 percent) developed interstitial lung disease, and 41 cases (14 percent) were found to be associated with internal malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/7\">",
"     7",
"    </a>",
"    ]. Juvenile DM is not associated with pulmonary disease or an increased risk for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H5#H5\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link&amp;anchor=H11#H11\">",
"     \"Malignancy in dermatomyositis and polymyositis\", section on 'Screening for cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13069029\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of cutaneous disease in DM can be challenging, and cutaneous manifestations are often more resistant to therapy than concomitant muscle involvement. Therapy for cutaneous disease is usually indicated due to the presence of severe pruritus and patient distress over the appearance of skin lesions.",
"   </p>",
"   <p>",
"    Data on therapies for cutaneous manifestations of DM are limited, and most data regarding this indication are in the form of case reports and retrospective reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. A 2005 systematic review found only four high-quality randomized controlled trials on DM, none of which specifically focused on skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequent inclusion of patients with different variants of DM within studies (eg, both adult and juvenile DM or both classic and amyopathic DM) and the concomitant administration of immunosuppressive therapies for muscle disease in many studies have made it difficult to interpret the available literature. Data on true monotherapy, particularly in the absence of concomitant topical or systemic glucocorticoids, is virtually nonexistent. The historical lack of standardized measures to assess responses to therapy has also compromised the systematic interpretation of published literature. The consistent use of validated, objective measures of response to therapy, such as the Cutaneous Dermatomyositis Disease Area and Severity Index, will be useful for interpreting the results of future studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2068757\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with classic DM, cutaneous disease improves during immunosuppressive treatment for muscle disease. However, skin manifestations can persist despite effective treatment of myositis. It is unknown whether early aggressive treatment of amyopathic DM influences risk for the development of myositis or other organ involvement.",
"   </p>",
"   <p>",
"    The initial management of the cutaneous manifestations of DM typically includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive photoprotection",
"     </li>",
"     <li>",
"      Antipruritic agents",
"     </li>",
"     <li>",
"      Topical corticosteroids or topical calcineurin inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients for whom symptoms are not adequately controlled with these measures, oral antimalarials are appropriate first-line systemic therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    may also be of benefit. Due to the potential for adverse effects, other systemic therapies usually are reserved for patients who are refractory to these measures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13069036\">",
"    <span class=\"h1\">",
"     PHOTOPROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with DM exhibit photosensitivity to ultraviolet radiation in experimental settings, and it is thought that sun exposure may exacerbate cutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/3\">",
"     3",
"    </a>",
"    ]. In disorders that are exacerbated by sun exposure, even limited sun exposure can be detrimental [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28087784\">",
"     'Photosensitivity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Year-round daily photoprotection with a broad-spectrum sunscreen with a sun protective factor (SPF) of at least 30 is recommended, and reapplication should occur every three to four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/17\">",
"     17",
"    </a>",
"    ]. Wide-brimmed hats, sun protective clothing, and avoidance of sun exposure should also be encouraged. Given the degree of photoprotection mandated in this patient population, consideration should be given to vitamin D status and vitamin D supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Photoprotection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H11#H11\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377187\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PRURITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is a prominent feature of DM and can have significant adverse effects on quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Pruritus can interfere with sleep patterns and activities of daily living and should be treated aggressively. Topical agents containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    , menthol, or camphor may provide temporary symptomatic relief.",
"   </p>",
"   <p>",
"    The addition of oral sedating antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ), or other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is often necessary to improve pruritus. Nonsedating antihistamines are not beneficial.",
"   </p>",
"   <p>",
"    Daily application of topical corticosteroid foams, sprays, gels, oils, shampoos, or solutions to the scalp can be useful in the management of scalp pruritus. High potency topical corticosteroid products can be used in patients in whom pruritus fails to improve with low or medium potency agents (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). Treatment with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    foam has been particularly beneficial in the practices of some experts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377239\">",
"    <span class=\"h1\">",
"     TOPICAL ANTIINFLAMMATORY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative safety of topical agents favors the use of these drugs in DM. However, only a minority of patients can be managed with topical agents alone; most patients require combination therapy with a systemic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13069050\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids are used to reduce the erythema and pruritus associated with DM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/19\">",
"     19",
"    </a>",
"    ]. Group I topical corticosteroids are often used to treat the hands, extensor surfaces, and scalp, where the risk of corticosteroid-induced cutaneous atrophy is low, while lower potency agents (group VI to VII) are used for disease in areas that are more prone to atrophy, such as facial erythema and the heliotrope eruption (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Daily application with occlusion increases the penetration and potency of topical corticosteroids, and the use of high potency topical corticosteroids under occlusion may be beneficial for refractory hyperkeratotic lesions, particularly those on the dorsal hands [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"     2",
"    </a>",
"    ]. When occlusion is not used, topical corticosteroids are generally applied twice daily. The inclusion of treatment free periods (eg, two weeks on, two weeks off therapy) can reduce the risk of local and systemic adverse effects.",
"   </p>",
"   <p>",
"    Although intralesional corticosteroid therapy is occasionally used for refractory lesions or for scalp disease, this often is impractical given the extent of cutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical corticosteroids can induce local cutaneous atrophy. In addition, systemic absorption can lead to adrenal suppression and other side effects, particularly when used in patients with widespread disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13069057\">",
"    <span class=\"h2\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports and a small, uncontrolled study have documented successful treatment of cutaneous disease in DM with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/8,20-23\">",
"     8,20-23",
"    </a>",
"    ]. All patients were on additional therapeutic agents at the time of treatment. In the uncontrolled study, six patients (five adults and one child) were treated with tacrolimus 0.1% ointment for six to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/23\">",
"     23",
"    </a>",
"    ]. Dramatic (&gt;90 percent) improvement was noted in two patients, and moderate (40 to 90 percent) or minimal (20 to 40 percent) improvement was noted in one and three patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a prospective study of five patients with cutaneous DM found a lack of benefit with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/24\">",
"     24",
"    </a>",
"    ]. No difference in disease severity was detected between skin treated with tacrolimus 0.1% ointment (twice daily for two months) and contralateral skin that was not treated with tacrolimus.",
"   </p>",
"   <p>",
"    Additional studies are necessary to determine the efficacy of topical calcineurin inhibitors for cutaneous manifestations of DM. We typically use these agents for patients who do not improve with topical corticosteroids or for long-term topical therapy in areas that are prone to cutaneous atrophy. Documentation of a beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    for cutaneous DM is limited to case reports documenting improvement after several months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/25\">",
"     25",
"    </a>",
"    ]. We personally have noted modest success with this drug.",
"   </p>",
"   <p>",
"    Pruritus or burning sensations at sites of application are potential adverse effects of topical calcineurin inhibitors. In addition, rare reports of the development of internal malignancies in patients treated with these agents led the US Food and Drug Administration to place a boxed warning on topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    drug labels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11395989\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, photoprotection and topical agents alone are insufficient for controlling the cutaneous disease of DM, leading to the need for systemic therapy. Antimalarial drugs are appropriate first-line therapies for these patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    may be used as an adjunctive or alternative agent. Although patients may exhibit improvement in cutaneous disease during treatment with systemic glucocorticoids for myositis, the limited evidence for efficacy of these drugs and the potential for serious adverse effects preclude their routine use in the initial management of cutaneous disease. (See",
"    <a class=\"local\" href=\"#H377771\">",
"     'Antimalarials'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13069078\">",
"     'Methotrexate'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11396032\">",
"     'Systemic glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377771\">",
"    <span class=\"h2\">",
"     Antimalarials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimalarials have been prescribed for the treatment of cutaneous DM since the 1950s. Although antimalarials can be effective for the treatment of the cutaneous manifestations of DM, they do not appear to be useful for associated muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/26\">",
"     26",
"    </a>",
"    ]. This observation suggests that the beneficial effects of antimalarials on the skin may be a result of photoprotection rather than systemic immunomodulation. Alternatively, the difference in efficacy may be a result of divergent pathogenetic mechanisms for skin and muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/14,27\">",
"     14,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377960\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have studied antimalarial therapy in the treatment of DM; evidence of efficacy is limited to small uncontrolled studies.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    (up to 6.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    based upon ideal body weight) partially or completely controls cutaneous disease in some patients. In addition, in patients who are receiving concomitant systemic glucocorticoids, antimalarials may reduce exacerbations of cutaneous disease during tapering of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    is supported by an open study of seven patients in whom cutaneous DM persisted during systemic glucocorticoid therapy or worsened during glucocorticoid tapering [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/28\">",
"     28",
"    </a>",
"    ]. The addition of hydroxychloroquine to the therapeutic regimen led to complete resolution of skin disease in three patients and partial improvement in the other four. Additional small, retrospective studies also demonstrate favorable results with hydroxychloroquine for cutaneous DM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail to respond adequately to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    can be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    (250 to 500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or can have quinacrine added to the treatment regimen. The dose of chloroquine should not exceed more than 4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    based upon the patient&rsquo;s ideal body weight. In the United States, chloroquine is used much less frequently than hydroxychloroquine due to concerns about a higher risk of drug-induced retinopathy with chloroquine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H14#H14\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Retinopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of quinacrine (100 mg once or twice daily) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    therapy can improve the response to treatment. In a retrospective case series in which 7 out of 17 patients (41 percent) with DM experienced at least near clearance of cutaneous disease with antimalarial therapy alone, four of the responders required the addition of quinacrine to hydroxychloroquine or chloroquine therapy to achieve this level of improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/33\">",
"     33",
"    </a>",
"    ]. This observation suggests that a subset of patients may benefit from combination antimalarial therapy after failure to respond sufficiently to monotherapy. In the United States, quinacrine can only be obtained at compounding pharmacies.",
"   </p>",
"   <p>",
"    Quinacrine does not cause retinopathy, which enables use of the drug in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    . In contrast, hydroxychloroquine and chloroquine, both of which can induce ocular damage, should",
"    <strong>",
"     not",
"    </strong>",
"    be prescribed together.",
"   </p>",
"   <p>",
"    Responses to antimalarial medications may not be evident until six to eight weeks after the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"     2",
"    </a>",
"    ]. Smoking may decrease the efficacy of antimalarial drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and smoking cessation should be encouraged in patients who receive antimalarial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378000\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular, gastrointestinal, hematologic, and neurologic adverse effects may occur secondary to antimalarial therapy. The risk of irreversible retinopathy is restricted to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    . Thus, patients treated with either of these drugs should have a baseline ophthalmologic examination prior to or within several months of initiation of therapy and require followup for the development of retinal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H7#H7\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H17#H17\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Ocular health'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous adverse effects related to antimalarial therapy also have been reported in patients with DM. In a retrospective case control study of 39 patients with DM, 12 (31 percent) developed a cutaneous drug eruption while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, worsening of cutaneous disease has been reported in two children with DM after the initiation of hydroxychloroquine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/38\">",
"     38",
"    </a>",
"    ]. Reversible yellow discoloration of the skin is a common adverse effect of quinacrine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13069078\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    can be effective for cutaneous disease in DM, the drug has a broader side effect profile than antimalarials, supporting the use of antimalarials as the initial choice of therapy in most patients. For patients who fail to improve adequately on antimalarial drugs, methotrexate can be added to antimalarial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/28,39\">",
"     28,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is a reasonable option for first-line systemic therapy for some patients. Unlike antimalarials, methotrexate is effective as a glucocorticoid-sparing agent for the treatment of DM-associated myositis. Thus, in patients who would benefit from methotrexate for the management of concomitant myositis, the drug is a reasonable first-line therapy for skin disease. Methotrexate can also be used as an alternative to antimalarial therapy in patients who cannot tolerate antimalarials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H21#H21\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378060\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for the cutaneous manifestations of DM has not been studied in randomized trials, and evidence for the support of this therapy is primarily limited to retrospective analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. In one retrospective study of 13 patients with cutaneous DM who were treated with methotrexate (2.5 to 30",
"    <span class=\"nowrap\">",
"     mg/",
"     <strong>",
"      week",
"     </strong>",
"     ),",
"    </span>",
"    eight achieved complete or almost complete clearance of skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/41\">",
"     41",
"    </a>",
"    ]. All patients who were simultaneously treated with systemic glucocorticoids were able to reduce or discontinue glucocorticoid therapy.",
"   </p>",
"   <p>",
"    The presence of an abundant lymphocytic infiltrate on skin biopsy seemed to portend an increased likelihood for a response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (7.5 to 20",
"    <span class=\"nowrap\">",
"     mg/",
"     <strong>",
"      week",
"     </strong>",
"     )",
"    </span>",
"    in a separate retrospective study in which 8 of 11 patients who failed to improve adequately with systemic glucocorticoids improved during methotrexate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/42\">",
"     42",
"    </a>",
"    ]. However, further investigations are necessary to confirm this finding.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is taken on a weekly basis and can be given orally, intramuscularly, subcutaneously, or intravenously. Typical doses for the treatment of DM range from 10 to 40",
"    <span class=\"nowrap\">",
"     mg/",
"     <strong>",
"      week",
"     </strong>",
"     .",
"    </span>",
"    &nbsp;Improvement usually occurs within four to eight weeks.",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or folinic acid (5",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    8 to 12 hours after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    administration in patients who do not respond sufficiently to folic acid) may decrease the incidence of some methotrexate-induced adverse effects. (See",
"    <a class=\"local\" href=\"#H378067\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378067\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal upset, stomatitis, and leukopenia can occur during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , but may be minimized by folic or folinic acid supplementation. Hepatotoxicity and pulmonary fibrosis are additional adverse effects associated with this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the risk of liver toxicity, preexisting liver disease and alcohol abuse are relative contraindications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . In addition, the risk of methotrexate toxicity is increased in patients with renal insufficiency; dosage must be adjusted in this population.",
"   </p>",
"   <p>",
"    Teratogenicity is another potential adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ; the drug should not be given to pregnant women. Methotrexate also should be avoided in women for one to three menstrual cycles prior to pregnancy, and in men for one month prior to an attempt to conceive.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    requires regular monitoring of complete blood counts, liver function tests, and renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11396032\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are the drugs of choice for the initial therapy DM-associated myositis, and may lead to clinical improvement in some patients with cutaneous manifestations of DM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the serious adverse effects associated with systemic glucocorticoids make them unfavorable for the treatment of skin disease, which often requires long term therapy.",
"   </p>",
"   <p>",
"    Examples of adverse effects of systemic glucocorticoid therapy include adrenal suppression, infections, osteoporosis, and osteonecrosis. The adverse effects of systemic glucocorticoids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the unpredictable efficacy and the many potential side effects of long-term systemic glucocorticoids, systemic glucocorticoids should not be used in the initial management of patients without clinical evidence of myositis or other systemic manifestations of DM that require the use of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13069085\">",
"    <span class=\"h1\">",
"     RECURRENT AND RESISTANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with DM may relapse after an initial response to the above therapies, or may fail to respond to these treatments. The management of patients with recalcitrant or recurrent DM is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28087734\">",
"    <span class=\"h1\">",
"     CALCINOSIS CUTIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of calcinosis cutis in patients with DM is reviewed elsewhere (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13069092\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatomyositis (DM) is an idiopathic inflammatory disorder for which cutaneous findings are a prominent feature. Inflammatory myopathy also frequently occurs in DM, but may precede, follow, or remain absent in patients with cutaneous manifestations of the disease. In some patients, cutaneous findings may persist after the successful treatment of myositis. (See",
"      <a class=\"local\" href=\"#H377280\">",
"       'Overview of clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H377365\">",
"       'Classification of cutaneous DM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DM often present with a pruritic, violaceous, macular, and papular eruption that primarily affects the upper body. Pruritus can be intense, and may have significant effects on patient quality of life. (See",
"      <a class=\"local\" href=\"#H377280\">",
"       'Overview of clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data on treatment options for the cutaneous manifestations of DM are limited. Photoprotection and management of pruritus are important components of management.",
"     </li>",
"     <li>",
"      For patients with cutaneous manifestations with DM, we suggest the use of topical corticosteroids for initial pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical calcineurin inhibitors are an additional therapeutic option for topical treatment. (See",
"      <a class=\"local\" href=\"#H13069036\">",
"       'Photoprotection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H377187\">",
"       'Management of pruritus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H377239\">",
"       'Topical antiinflammatory agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail to improve with photoprotection and topical treatment, we suggest the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (up to 6.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      based upon ideal body weight) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients who do not improve with hydroxychloroquine therapy, we suggest the addition of quinacrine (100 mg once or twice daily) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H377771\">",
"       'Antimalarials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (10 to 40",
"      <span class=\"nowrap\">",
"       mg/",
"       <strong>",
"        week",
"       </strong>",
"       )",
"      </span>",
"      may also be useful in the management of patients with cutaneous DM. For patients who fail to improve adequately with antimalarials, we suggest the addition of methotrexate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Methotrexate can also be used as a first-line agent for skin disease in patients with concomitant myositis or as an alternative to antimalarial therapy in patients who cannot tolerate antimalarial drugs. (See",
"      <a class=\"local\" href=\"#H13069078\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic glucocorticoids are not indicated for the initial management of cutaneous disease. The response to systemic glucocorticoids is unpredictable, and the adverse effects associated with long term therapy limit the use of these drugs for cutaneous DM. (See",
"      <a class=\"local\" href=\"#H11396032\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/1\">",
"      Hundley JL, Carroll CL, Lang W, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006; 54:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/2\">",
"      Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother 2004; 5:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/3\">",
"      Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed 2004; 20:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/4\">",
"      Sontheimer RD. Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem Photobiol 1996; 63:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/5\">",
"      Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol 1994; 131:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/6\">",
"      Callen JP. Photosensitivity in collagen vascular diseases. Semin Cutan Med Surg 1999; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/7\">",
"      Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin&eacute; myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/8\">",
"      Jorizzo JL. Dermatomyositis: practical aspects. Arch Dermatol 2002; 138:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/9\">",
"      Klein RQ, Teal V, Taylor L, et al. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol 2007; 57:937.",
"     </a>",
"    </li>",
"    <li>",
"     Jorizzo, JL, Carroll, CL, Sanueza, O. Dermatomyositis. In: Dermatology, Bolognia, JL, Jorizzo, JL, Rapini, RP, et al (Eds), Elsevier Limited, Spain 2008. p.575.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/11\">",
"      Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/12\">",
"      Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008; 59:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/13\">",
"      Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/14\">",
"      Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005; :CD003643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/15\">",
"      Klein RQ, Bangert CA, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/16\">",
"      Yassaee M, Fiorentino D, Okawa J, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol 2010; 162:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/17\">",
"      Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol 2006; 24:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/18\">",
"      Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol 2004; 29:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/19\">",
"      Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol 2006; 7:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/20\">",
"      Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/21\">",
"      Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol 2003; 148:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/22\">",
"      Lampropoulos CE, D' Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005; 64:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/23\">",
"      Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/24\">",
"      Garc&iacute;a-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology 2004; 209:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/25\">",
"      Kim JE, Jeong MG, Lee HE, et al. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol 2011; 23:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/26\">",
"      Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996; 5 Suppl 1:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/27\">",
"      Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/28\">",
"      Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984; 10:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/29\">",
"      James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxchloroquine. J Rheumatol 1985; 12:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/30\">",
"      Cosnes A, Amaudric F, Gherardi R, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995; 131:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/31\">",
"      Dawkins MA, Jorizzo JL, Walker FO, et al. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 1998; 38:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/32\">",
"      Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/33\">",
"      Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005; 141:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/34\">",
"      Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/35\">",
"      Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25:1716.",
"     </a>",
"    </li>",
"    <li>",
"     ACR Position Statement: Committee on Rheumatologic Care.  Screening for hydroxychloroquine retinopathy.  www.rheumatology.org/publications/position/hydroxyp2.asp?aud_mem. 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/37\">",
"      Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/38\">",
"      Bloom BJ, Tucker LB, Klein-Gitelman M, et al. Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J Rheumatol 1994; 21:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/39\">",
"      Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995; 32:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/40\">",
"      Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/41\">",
"      Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997; 36:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15513/abstract/42\">",
"      Hornung T, Ko A, T&uuml;ting T, et al. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol 2012; 37:139.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13771 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15513=[""].join("\n");
var outline_f15_9_15513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13069092\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13068987\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377280\">",
"      OVERVIEW OF CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28087755\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101092388\">",
"      Disease course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28087784\">",
"      Photosensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377365\">",
"      CLASSIFICATION OF CUTANEOUS DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11395954\">",
"      Classic DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2068610\">",
"      Amyopathic DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2068617\">",
"      Hypomyopathic DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2068718\">",
"      Postmyopathic DM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11396053\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953899\">",
"      Indications for biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28087829\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13069029\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2068757\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13069036\">",
"      PHOTOPROTECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377187\">",
"      MANAGEMENT OF PRURITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377239\">",
"      TOPICAL ANTIINFLAMMATORY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13069050\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13069057\">",
"      Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11395989\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H377771\">",
"      Antimalarials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H377960\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378000\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13069078\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378060\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378067\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11396032\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13069085\">",
"      RECURRENT AND RESISTANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28087734\">",
"      CALCINOSIS CUTIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13069092\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13771|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/45/44754\" title=\"picture 1A\">",
"      Gottron papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/48/6915\" title=\"picture 1B\">",
"      Gottron sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/41/18069\" title=\"picture 1C\">",
"      Gottrons sign 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/6/29793\" title=\"picture 2A\">",
"      Dermatomyositis - heliotrope eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/10/29860\" title=\"picture 2B\">",
"      Dermatomyositis - heliotrope eruption on eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/58/13217\" title=\"picture 2C\">",
"      Dermatomyositis - neck and chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/41/13969\" title=\"picture 2D\">",
"      Dermatomyositis - upper back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/5/4181\" title=\"picture 3\">",
"      Dermatomyositis scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/41/27284\" title=\"picture 4\">",
"      Dermatomyositis - hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13771|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=related_link\">",
"      Management of refractory cutaneous dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=related_link\">",
"      Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_9_15514="Management of supraventricular tachycardia in children";
var content_f15_9_15514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of supraventricular tachycardia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15514/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15514/contributors\">",
"     Anne M Dubin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15514/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/9/15514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/9/15514/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/9/15514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular tachycardia (SVT) can be defined as an abnormally rapid heart rhythm originating above the ventricles, often (but not always) with a narrow QRS complex; it conventionally excludes atrial flutter and atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of SVT in children will be reviewed here. Two major issues will be addressed: acute management to terminate the arrhythmia, and chronic therapy to prevent recurrence. The clinical features of the different types of SVT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute management of the child who presents in SVT can be a challenge because the exact mechanism of the tachycardia often is unknown. The treatment strategy depends upon the patient's presentation and clinical status (hemodynamically stable or unstable). The approach consists of initiating therapy while continuing to assess the patient's condition (",
"    <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"     table 1",
"    </a>",
"    ). The following discussion is generally in agreement with the Pediatrics Advanced Life Support (PALS) guidelines published by the American Heart Association in collaboration with the International Liaison Committee on Resuscitation (",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An infant or child who presents with a tachyarrhythmia should have an immediate hemodynamic assessment and a 15-lead ECG (12 standard leads plus leads V3R and V4R [right sided leads analogous to V3 and V4 on the left] and V7 [left posterior axillary line at V4 level]). Continuous ECG monitoring during therapeutic maneuvers provides insight into the cause of tachycardia and helps in the planning of chronic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hemodynamic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important initial clinical determination to make in children presenting with a tachyarrhythmia is whether signs and symptoms related to the rapid heart rate are present. These include hypotension, heart failure, and signs of shock, pallor, or decreased level of consciousness. Signs in infants may include irritability, tachypnea, and poor feeding.",
"   </p>",
"   <p>",
"    Affected children can be asymptomatic except for palpitations, or may be unconscious with signs of cardiovascular collapse. The acute management depends on whether the patient is hemodynamically stable or not (",
"    <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the child with tachycardia\", section on 'Algorithmic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemodynamically unstable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable patients with hemodynamic compromise, such as unconsciousness or shock with severe heart failure, require immediate termination of the tachyarrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the child with tachycardia\", section on 'Shock'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct current cardioversion at 0.5 to 2.0",
"    <span class=\"nowrap\">",
"     J/kg",
"    </span>",
"    should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A narrow complex tachycardia should be converted in synchronous mode in which a shock is not delivered during the vulnerable repolarization period; this will avoid possible precipitation of ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardioversion in children may be performed with pediatric electrode paddles (surface area 21 cm",
"    <sup>",
"     2",
"    </sup>",
"    ). However, the use of adult electrode paddles (surface area 83 cm",
"    <sup>",
"     2",
"    </sup>",
"    ) results in lower transthoracic impedance and therefore higher current flow, which may be preferable in children over 10 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the child should be given adequate sedation or general anesthesia before the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Rarely, a child is too critically ill to delay the procedure for administration of general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of a child with a tachyarrhythmia is discussed in detail separately. The following findings support the presence of an SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History incompatible with sinus tachycardia",
"     </li>",
"     <li>",
"      P waves absent or abnormal",
"     </li>",
"     <li>",
"      Heart rate does not vary with activity",
"     </li>",
"     <li>",
"      The presence of abrupt changes in heart rate",
"     </li>",
"     <li>",
"      Rate usually &gt;220",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      in infants and &gt;180",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      in children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Establishing the diagnosis of the two main causes of SVT, atrioventricular reentrant tachycardia (AVRT), including the Wolff-Parkinson-White (WPW) syndrome, and atrioventricular nodal reentrant tachycardia (AVNRT), is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H19#H19\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vagal maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who have mild or no symptoms, vagal maneuvers should be attempted while supplies and personnel are assembled to proceed to medical therapy, if needed. These maneuvers should be performed while the ECG is continuously monitored. The electrocardiographic pattern seen during termination of the tachycardia can help determine its mechanism.",
"   </p>",
"   <p>",
"    The vagal maneuver usually used in infants or young children is application of a bag filled with ice and cold water over the face for 15 to 30 seconds. This elicits the diving reflex, frequently interrupting the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/7\">",
"     7",
"    </a>",
"    ]. This maneuver is successful in 30 to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another method that may be successful in infants is rectal stimulation using a thermometer. In older children, bearing down (Valsalva maneuver) for 15 to 20 seconds provides vagal stimulation.",
"   </p>",
"   <p>",
"    Carotid massage and orbital pressure should",
"    <strong>",
"     not",
"    </strong>",
"    be performed in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the vagal maneuver does not convert SVT that is hemodynamically stable to normal rhythm, an intravenous catheter should be placed for the administration of antiarrhythmic drugs. The most commonly used pharmacologic agent for acute management of SVT is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    ;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    are sometimes given for tachycardia that is refractory to adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     Digoxin",
"    </a>",
"    is not usually used because of the delay in achieving therapeutic levels and the narrow therapeutic margin with the risk of serious toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, digoxin should",
"    <strong>",
"     not",
"    </strong>",
"    be given if Wolff-Parkinson-White is suspected, since it may potentiate accessory pathway conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     Adenosine",
"    </a>",
"    is considered the drug of choice for acute medical conversion of SVT (",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef51178 \" href=\"UTD.htm?40/50/41775\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. Adenosine interacts with A1 receptors on the surface of cardiac cells; the resulting effects include slowing of the sinus rate and an increase in the atrioventricular (AV) nodal conduction delay [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/12\">",
"     12",
"    </a>",
"    ]. This interrupts the reentrant circuit of tachycardias that require the AV node for reentry, which account for the great majority of cases of SVT in children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    administration, the patient should be supine and should have ECG and blood pressure monitoring. The drug is administered by rapid intravenous injection over one to two seconds at a site as close to the central circulation as possible. This is followed immediately by a 5 mL normal saline flush to speed delivery to the heart, which is needed because the drug is rapidly metabolized to an inactive form.",
"   </p>",
"   <p>",
"    The usual initial dose is 0.1",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    if no response is seen within two minutes, the dose is doubled [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An alternative regimen consists of an initial bolus of 0.05",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    if no response is seen within two minutes, the dose is increased by 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    increments every two minutes until termination of the arrhythmia or a maximum dose of 0.25 to 0.35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 12 mg is given.",
"   </p>",
"   <p>",
"    The average effective dose is approximately 0.13",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/17\">",
"     17",
"    </a>",
"    ]. However, because",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    is metabolized by an enzyme on the red cell surface, a higher dose is required when given through a peripheral compared to a central vein [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     Adenosine",
"    </a>",
"    terminates 80 to 95 percent of episodes of AVRT, which accounts for almost three-quarters of episodes of SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and approximately 75 percent of episodes due to other causes of SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. Early recurrence of the SVT after termination occurs in 25 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vagal stimulation caused by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    is brief and self-limited. The onset of effect is almost immediate, and always within 30 seconds of the infusion. The half-life is less than 5 to 10 seconds. The effects of adenosine are diminished by methylxanthines such as caffeine or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Side effects, including flushing, nausea, vomiting, vague feeling of discomfort, chest pain, and dyspnea are not uncommon with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    , but usually resolve rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/15,17-20\">",
"     15,17-20",
"    </a>",
"    ]. Serious side effects, such as arrhythmias, are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/18\">",
"     18",
"    </a>",
"    ]. Adenosine can precipitate atrial fibrillation, although this usually terminates spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. In a series of 38 children with SVT, significant complications occurred in four: atrial fibrillation, ventricular tachycardia, apnea, and one minute of asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     Adenosine",
"    </a>",
"    should be avoided or used with caution in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with Wolff-Parkinson-White (WPW), AF can degenerate into ventricular fibrillation. As a result, caution should be used when giving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"       adenosine",
"      </a>",
"      if WPW is a possible mechanism, and emergency resuscitation equipment should be available [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"       Adenosine",
"      </a>",
"      should be avoided in patients with a wide QRS complex tachycardia, if the specific arrhythmia is not identified, since adenosine can provoke severe hemodynamic deterioration in those who have ventricular tachycardia rather than an SVT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link\">",
"       \"Management and evaluation of wide QRS complex tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"       Adenosine",
"      </a>",
"      is contraindicated in patients with preexisting second or third degree heart block or sinus node disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bronchospasm has been reported with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    in patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], but is not common in other children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/18\">",
"     18",
"    </a>",
"    ]. The mechanism is uncertain but may be related to stimulation or enhancement of mast cell-derived mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     Verapamil",
"    </a>",
"    is an effective acute therapy to slow AV nodal conduction and terminate the arrhythmia in older children with SVT. Verapamil is administered as an intravenous infusion in a dose of 0.1 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    with a maximum dose of 10 mg.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     Adenosine",
"    </a>",
"    is preferred for first-line therapy because of its very short duration of action. In addition, there are a number of settings in which",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    should not be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants less than one year of age because it may cause apnea, hypotension, bradycardia, and cardiovascular collapse [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. The mechanism of this complication may be a poorly developed sarcoplasmic reticulum in infants, so that myocardial contractility depends solely on calcium channels.",
"     </li>",
"     <li>",
"      In children with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3,25\">",
"       3,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children suspected to have WPW, since it may potentiate conduction down an antegrade conducting pathway and provoke ventricular fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children with a wide QRS complex tachycardia since it can provoke severe hemodynamic deterioration in those who have ventricular tachycardia rather than an SVT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, the Pediatric ALS guidelines discourage the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Procainamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;SVT that is refractory to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    may respond to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    . Procainamide is a class IA antiarrhythmic drug that acts primarily by inhibiting phase 0 (sodium-dependent) depolarization and slows atrial conduction. Unlike adenosine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    , procainamide acts by slowing conduction within the myocardium itself, rather than by blocking reentry at the AV node. As a result, procainamide may be used safely in patients with WPW without the risk of provoking accessory pathway conduction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     Procainamide",
"    </a>",
"    is administered intravenously. In patients under one year of age, a loading dose of 7 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is given over 30 to 45 minutes. In older children, the loading dose is 15",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    This is followed by a continuous infusion of procainamide starting at 40 to 50",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. Plasma levels should be measured four hours after completion of the loading dose, during the maintenance infusion.",
"   </p>",
"   <p>",
"    Negative inotropic effects may occur following the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    . In addition, procainamide can prolong the QT interval and therefore should not be given with other drugs that have the same effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is a class III antiarrhythmic agent. The intravenous preparation, which is used for the acute therapy of SVT, prolongs the refractory period of the AV node and, to a lesser degree, the duration of the action potential and the refractory period of both atrial and ventricular myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/28\">",
"     28",
"    </a>",
"    ]. It is usually used for SVT that is refractory to other agents (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/29\">",
"     29",
"    </a>",
"    ] and, like procainamide, it can be used safely in patients with WPW. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is administered intravenously, and a variety of regimens have been used. We typically recommend a bolus infusion of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 20 to 60 minutes. If there is no response, the bolus dose is repeated up to a total of 20",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    If the patient responds, this is followed by a continuous infusion of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    A number of small series have reported the efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    in the acute treatment of SVT in children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 40 children (mean age 5.4 years) who failed standard therapy,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      successfully converted 16 of the 28 (57 percent) children with SVT to sinus rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/29\">",
"       29",
"      </a>",
"      ]. An additional eight patients with junctional ectopic tachycardia had sufficient slowing of the rate to improve hemodynamic function.",
"     </li>",
"     <li>",
"      In a report of 61 children (mean age 4.1 years), the response time was shorter and the overall success rate of conversion was greater in patients who received higher dosing regimens of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/32\">",
"       32",
"      </a>",
"      ]. In this study, three loading dose regimens (low: 1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      medium: 5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and high: 10",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      were used, followed by three continuous infusion rates (low: 1, medium: 5, and high 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). Additional rescue bolus (up to five) could be administered 70 minutes after the loading dose. For the low, medium, and high doses groups, the times to respond were 28.2, 2.6, and 2.1 hours, respectively; and successful conversions at 70 minutes were seen in 16, 25, and 41 percent of each respective group. At 48 hours, successful conversions were seen in 47, 80, and 73 percent of each respective group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects are relatively common.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 31 episodes of tachyarrhythmias in children, adverse effects occurred in 18 (58 percent), but none required cessation of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the first report of 40 patients discussed above [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/29\">",
"       29",
"      </a>",
"      ], the most important side effects were mild hypotension in four and temporary pacing for bradycardia in one. No proarrhythmia was observed.",
"     </li>",
"     <li>",
"      In the second report discussed above, 87 percent of patients reported side effects including hypotension, nausea, vomiting, atrioventricular block, and bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/32\">",
"       32",
"      </a>",
"      ]. There were too few of each type of adverse event to determine whether any of these were associated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      . Ten patients were withdrawn from the study because of significant adverse effects (hypotension, bradycardia, and atrioventricular block).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many more patients treated with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    were evaluated in a review of the published literature that was not limited to children or to patients with SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/28\">",
"     28",
"    </a>",
"    ]. The major acute side effect was hypotension. Proarrhythmia was noted in 2 to 3 percent; it is usually manifest as torsades de pointes but ventricular fibrillation can occur. Other cardiac side effects were less common. Intravenous therapy is not associated with the chronic side effects seen with prolonged oral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transesophageal pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transesophageal pacing may be a useful adjunct to therapy for SVT in a child who is hemodynamically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ]. It can be used to determine the mechanism of and to terminate the tachycardia. The technique involves electrical cardiac stimulation until the tachyarrhythmia resolves or until other therapies can be initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3,34\">",
"     3,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two major approaches to transesophageal pacing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial overdrive pacing, in which atrial pacing commences at a rate slower than the tachyarrhythmia, with gradual acceleration",
"     </li>",
"     <li>",
"      Extrastimulation, in which the atrium is paced at a constant rate, with extra stimuli inserted at progressively shorter intervals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one report largely involving adults, AVRT and AVNRT were successfully terminated with transesophageal pacing in 62 of 63 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/34\">",
"     34",
"    </a>",
"    ]. However, transesophageal pacing requires specialized personnel and equipment. Sedation of the child may be necessary because the procedure can be quite uncomfortable. Thus, although useful, therapeutic pacing generally is considered only when the patient is hemodynamically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     Digoxin",
"    </a>",
"    is not usually used because of the delay in achieving therapeutic levels and the narrow therapeutic margin with the risk of serious toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, digoxin should",
"    <strong>",
"     not",
"    </strong>",
"    be given if WPW is suspected, since it may potentiate accessory pathway conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with SVT are often symptomatic with a high proportion of cases presenting with some signs or symptoms of cardiac failure. In a case series of 109 neonates from a single tertiary center treated over a 27 year span (1971 to 1997), medical management was acutely successful in most of the patients with conversion to sinus rhythm in over 90 percent of patients after 24 hours of diagnosis, and in 99 percent of patients after one week [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/35\">",
"     35",
"    </a>",
"    ]. In eight patients, there was spontaneous conversion to sinus rhythm, and vagal stimulation was successful in 18 of the 41 cases in which it was attempted. There were seven deaths, five due to cardiac failure, and two not related to SVT. Patients who required multiple drugs or more than six days to obtain arrhythmia control were more likely to have recurrent episodes of SVT requiring chronic therapy.",
"   </p>",
"   <p>",
"    Another study reviewed data from the Pediatric Health Information System of 171 infants (&lt;1 year of age) from 2003 to 2008 that included 65 neonates (&lt;30 days of age, 38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/36\">",
"     36",
"    </a>",
"    ]. In this cohort, although almost two-thirds of neonates were admitted to the ICU at some point during their inpatient stay, there were no deaths and 95 percent of the infants were discharged home. Most patients were treated using a beta blocker",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    , and fewer than half required second-line agents such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Only two patients underwent catheter ablation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CHRONIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the acute episode is terminated, a 12-lead ECG should be performed to look for evidence of Wolff-Parkinson-White (WPW) syndrome (the presence of a wide QRS complex with a \"delta wave\") (",
"    <a class=\"graphic graphic_waveform graphicRef75578 \" href=\"UTD.htm?34/55/35706\">",
"     waveform 2",
"    </a>",
"    ). In addition, an echocardiogram should be obtained to assess for structural heart disease, since SVT can be associated with congenital disorders (21 percent of patients referred for catheter ablation in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronic management of SVT includes several options, each with advantages and disadvantages. The specific approach should be tailored to the individual patient based upon age and severity of symptoms (",
"    <a class=\"graphic graphic_algorithm graphicRef51645 \" href=\"UTD.htm?11/18/11567\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to the chronic management of children with recurrent episodes of SVT is expectant, with no specific treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ]. In this approach, the patient and family are taught to recognize SVT and to terminate episodes using vagal maneuvers. The rationale for this strategy is that patients who present at less than five years of age have a high likelihood of outgrowing their SVT and may not require chronic therapy that may be associated with side effects. In addition,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    , which is the most commonly used drug, may not be more effective than expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If this is the first episode of SVT and there is no evidence of ventricular dysfunction and no hemodynamic instability, we offer the parents the option of expectant management and no specific treatment. We monitor the child for at least 24 hours and teach the parents how to check the heart rate. Vagal maneuvers may include using an ice bag applied to the face, performing the Valsalva maneuver, assuming a head-down position, inducing the gag reflex, and other techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Vagal maneuvers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In infants who cannot complain of palpitations, recurrences of SVT may not be promptly detected [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ]. While having the parents check the heart rate may be effective, we are more likely to consider the use of medications in this situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy is used in children who have frequent episodes of SVT or who become symptomatic during infrequent episodes. The objective of medical treatment is to prevent episodes of SVT or to lessen symptoms during a recurrence. Another form of treatment is the use of \"pulsed\" or \"cocktail\" therapy, in which the patient takes an antiarrhythmic drug only during an episode of SVT in order to terminate the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3,40,41\">",
"     3,40,41",
"    </a>",
"    ], although we do not generally use this approach.",
"   </p>",
"   <p>",
"    Specific characteristics may help identify those patients who require long-term therapy. In one study, infants with SVT and structurally normal hearts were classified as simple (completely controlled by one medication) or complex (recurrent episodes needing at least one medication change for control) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/42\">",
"     42",
"    </a>",
"    ]. Complex (recurrent) SVT was associated with young age at presentation (10 versus 50 days), ventricular dysfunction at presentation, and slow retrograde conduction properties of the accessory pathway. Gender, initial medication, duration of treatment, cycle length in SVT or sinus rhythm, and presence of preexcitation were similar between the groups.",
"   </p>",
"   <p>",
"    The benefits of medication therapy remain uncertain due to the lack of controlled studies. For infants, retrospective and anecdotal data suggest that recurrence rates with drug therapy range from 40 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ]. Conclusions about whether some drugs are more effective than others are difficult to reach from the available reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     First-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our first-line agent for SVT is a beta blocker, largely because beta blockers avoid the more serious side effects that can be seen with other antiarrhythmic drugs.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     Digoxin",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with Wolff-Parkinson-White (WPW) since it can accelerate conduction across the accessory pathway, particularly in patients who develop atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3,43\">",
"     3,43",
"    </a>",
"    ]. Side effects of beta blockers include hypotension, emotional disturbances, and nightmares. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no difference in SVT recurrence in infants treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    versus",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This was best illustrated in the SAMIS (Study of Antiarrhythmic Medications in Infancy) trial, a multicenter study of 61 infants, which showed similar six-month recurrence-free status for patients treated with propranolol and digoxin (67 versus 79 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/45\">",
"     45",
"    </a>",
"    ]. No deaths and no serious adverse events related to study medications were observed.",
"   </p>",
"   <p>",
"    In infants, we use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    (2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into four doses). In older children we use a longer acting beta blocker,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"     atenolol",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day).",
"   </p>",
"   <p>",
"    As noted above,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    , a calcium channel blocker, is contraindicated in children less than one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] and can cause accessory pathway acceleration and is not often used in WPW. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Verapamil'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive therapy for SVT that does not respond to first-line therapy is radiofrequency ablation (RFA). However, because the risk of morbidity and mortality of this procedure is high in infants, pharmacologic therapy is usually attempted. Little information is available on the outcome of chronic medical treatment in older children, who are more often treated with RFA once their weight exceeds 15 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs that may be effective alone or in combination include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=see_link\">",
"     sotalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/38,46-49\">",
"     38,46-49",
"    </a>",
"    ]. The efficacy of these agents ranges from 20 to 100 percent. However, the results are difficult to interpret because of undocumented natural history, variations in practice, and lack of controlled trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential efficacy of these drugs is illustrated by the following observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 39 infants with SVT due to atrioventricular (AV) reentry, control was achieved in five of six treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=see_link\">",
"       flecainide",
"      </a>",
"      compared with 14 of 33 treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/37\">",
"       37",
"      </a>",
"      ]. In addition, flecainide controlled all 19 patients who did not respond to digoxin. The authors concluded that, compared with previous natural history studies, digoxin may have provided no benefit.",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      was evaluated in 47 patients ranging in age from 23 weeks of gestation to 29 years; 24 had SVT. Treatment was judged effective in 32 (68 percent), but 11 of these required the addition of a second drug [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case series of 78 infants with SVT, including 48 neonates and 36 infants with congenital heart disease who had failed monotherapy with another antiarrhythmic medication,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=see_link\">",
"       sotalol",
"      </a>",
"      therapy controlled SVT in 70 patients (90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/50\">",
"       50",
"      </a>",
"      ]. Notably, this study utilized a dosing regimen which significantly exceeded that recommended on the basis of prior pharmacokinetic study in this age range (median dose 152",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day, range 65 to 244",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day).",
"      </span>",
"      No patients experienced significant QTc prolongation or proarrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The side effects of these drugs are more serious than those seen with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    and beta blockers. They include proarrhythmia, myocardial depression, and, with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    , hypothyroidism and pulmonary fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"     \"Major side effects of class I antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of combinations of drugs is variable from institution to institution as well as from patient to patient. Such an approach is reserved for patients for difficult to control arrhythmia and requires careful monitoring for proarrhythmic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA), which was first reported as a successful alternative to drug therapy in children in 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/51\">",
"     51",
"    </a>",
"    ], is the definitive therapy for SVT. In contrast, direct current ablation, which was employed prior to the development of RFA, was associated with a high incidence of complications and is no longer in clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;RFA is performed as part of an invasive electrophysiology (EP) study. Sedation or general anesthesia is generally necessary to minimize discomfort and prevent patient movement during the procedure; general anesthesia may be used, especially in patients less than 10 to 12 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/3,54\">",
"     3,54",
"    </a>",
"    ]. The study is performed in two stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, transvenous catheter electrodes are inserted and manipulated for pacing and recording. The pattern of recordings obtained during normal sinus rhythm, in response to pacing, and during the SVT (if it can be induced) is used to make a definitive diagnosis of the mechanism of the SVT.",
"     </li>",
"     <li>",
"      After the mechanism of SVT is determined, and the accessory pathway or AV nodal pathway is localized, a modified catheter is used that can deliver radiofrequency energy, which cauterizes the myocardial tissue and destroys the pathway. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"       \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"       \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial success rates for RF ablation in children can exceed 90 percent, although SVT can recur late after treatment. The following studies illustrate the range of published results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Pediatric Radiofrequency Catheter Ablation Registry prospectively evaluated the initial outcome of RF ablation in 481 infants and children with SVT (97 percent with structurally normal hearts) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/55\">",
"       55",
"      </a>",
"      ]. The procedure was immediately successful in 95 percent of cases with accessory pathways and 99 percent with atrioventricular nodal reentrant tachycardia (AVNRT). At three years, the freedom from arrhythmia recurrence was 77 and 71 percent for accessory pathways and AVNRT, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis from a single center, 410 RFA procedures were performed in 346 children and young adults over a five-year period, almost all with SVT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/14\">",
"       14",
"      </a>",
"      ]. Repeat procedures were necessary for recurrent arrhythmia in 64 patients (18 percent). When repeat procedures were included, the final success rate of RFA was 90 percent (96 percent for atrioventricular reentrant tachycardia (AVRT) and 83 percent for AVNRT). Over the five-year study period, initial procedural success rates increased from 80 to 100 percent, while recurrence rates declined from 20 to &lt;5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the 4500 children evaluated in these two reports, there were a total of three deaths within two months of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/14,56\">",
"     14,56",
"    </a>",
"    ]. The total complication rates ranged from 1.2 to 3.2 percent. In the Registry data, the most common complications were AV block (25), cardiac perforation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericardial effusion (24), brachial plexus injury (10), emboli (four CNS and four other), and pneumothorax (seven) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/56\">",
"     56",
"    </a>",
"    ]. Risk factors for complications are patient age less than four years, patient weight &lt;15 kg, and center inexperience with the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for RFA are based upon an assessment of the benefits and risks and continue to evolve. Consensus guidelines on indications for RFA in children have been developed by the North American Society of Pacing and Electrophysiology (NASPE) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/54\">",
"     54",
"    </a>",
"    ]. There was consistent agreement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supportive data (class I indication) that RFA was beneficial in patients with SVT in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wolff-Parkinson-White (WPW) syndrome after an episode of aborted sudden cardiac death.",
"     </li>",
"     <li>",
"      WPW syndrome at high risk for sudden death, which was defined as syncope with rapid conduction antegrade across the accessory pathway.",
"     </li>",
"     <li>",
"      Recurrent or chronic SVT associated with ventricular dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other indications for RFA include patients older than five years of age with frequent symptomatic episodes of SVT who do not respond to antiarrhythmic therapy. In many cases, elective RFA is considered a preferred alternative to chronic antiarrhythmic therapy. However, the procedure should be avoided in patients younger than five years of age or 15 kg body weight because of their increased risk of complications. If the child is older than five years and weighs more than 15 kg, we offer the family the options of RFA or drug therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef51645 \" href=\"UTD.htm?11/18/11567\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The role of RFA in patients with asymptomatic WPW remains uncertain. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Asymptomatic Wolff-Parkinson-White (WPW) syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the role of catheter-based cryoablation in children with SVT. An initial report showed that this modality can be safely performed in children as small as 20 kg and that it may be more effective for septal tachycardias due to AVNRT than those due to AVRT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/59\">",
"     59",
"    </a>",
"    ]. A comparison of cryoablation using a 4 mm cryocatheter and radiofrequency ablation in pediatric AVNRT found similar short-term efficacy (95 versus 100 percent), but higher recurrence rates in the cryoablation group (8 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a follow-up study, 61 of 73 children were evaluated at a mean of 3.1 years after initial cryoablation for AVNRT, which was performed between 2003 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/61\">",
"     61",
"    </a>",
"    ]. Procedural complications included transient atrioventricular block in 10 patients, and new arrhythmias in two patients. Four patients had recurrence of AVNRT after initial successful ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of RFA for the definitive treatment of SVT in children has led to a marked decline in the need for surgical intervention. Exceptions include the rare instances in which an arrhythmia is refractory to attempted RFA and those occasions in which another cardiac surgical procedure is planned as part of the patient's management (such as tricuspid valve repair for Ebstein's anomaly) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC WOLFF-PARKINSON-WHITE (WPW) SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of ventricular fibrillation (VF) in asymptomatic adults is thought to be very low, ranging from almost zero to about 0.1 percent per year, there remain concerns about the risk of sudden cardiac death (SCD) based upon case reports in children in which SCD was the first manifestation of WPW. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H15#H15\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Ventricular fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is difficult to accurately determine the risk of SCD in an asymptomatic child with WPW, electrophysiologic study (EPS) appears to be a useful tool for risk assessment.",
"   </p>",
"   <p>",
"    This was illustrated in a prospective study of 184 asymptomatic Italian children (mean age 10 years, range 8 to 12 years) with WPW syndrome who underwent an electrophysiologic study (EPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/65\">",
"     65",
"    </a>",
"    ]. Over a median follow-up of 57 months post-EPS, 133 patients experienced no arrhythmic events. The remaining 51 patients had a first arrhythmic event at a median 20 months post-EPS, 19 of which were potentially life-threatening (defined as preexcited atrial fibrillation lasting at least one minute, with the shortest RR interval &lt;250 msec). Three of the children presented with sudden death, and three with syncope. The remaining 13 experienced only minimal or atypical symptoms including nausea, sudden tiredness with anxiety, and abdominal pain with swelling.",
"   </p>",
"   <p>",
"    On multivariate analysis, life-threatening arrhythmic events were associated with the two EPS findings of multiple accessory pathways, and a short anterograde effective refractory period of the accessory pathway (less than 240 msec).",
"   </p>",
"   <p>",
"    An earlier study in 60 children undergoing surgery for WPW, 10 of whom had a history of cardiac arrest, also found that conduction characteristics of the accessory pathway appeared to be a sensitive predictor for risk of life-threatening arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/66\">",
"     66",
"    </a>",
"    ]. A preexcited interval (&lt;220 msec) occurred in all of the children with cardiac arrest.",
"   </p>",
"   <p>",
"    Although the results of these two studies suggest that EPS may be able to identify children with asymptomatic WPW syndrome who would benefit from ablation therapy, concern has been raised that the rate of observed events in the Italian study population was about 5 to 10 times greater than reported in other symptomatic and asymptomatic patients with WPW. As a result, further studies are needed to confirm whether the risks and costs of EPS are outweighed by its ability to identify asymptomatic patients with WPW who are at risk for life-threatening arrhythmic events.",
"   </p>",
"   <p>",
"    EPS is an invasive procedure, and the use of noninvasive risk stratification may be helpful in evaluating and managing asymptomatic children with WPW. Ambulatory monitoring and exercise testing are predictive for significant cardiac sequelae. As an example, intermittent loss of preexcitation (premature activation of part of the ventricular myocardium by an anomalous pathway bypassing the atrioventricular node), including loss of preexcitation with exercise, is associated with a decreased risk of sudden death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H21#H21\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Ambulatory monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H22#H22\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Exercise testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2012, the Pediatric Electrophysiology Society in conjunction with the Heart Rhythm Society, American College of Cardiology, American Heart Association, and American Academy of Pediatrics published a consensus statement regarding the best approach to management of asymptomatic children with Wolff-Parkinson-White (WPW) syndrome (",
"    <a class=\"graphic graphic_algorithm graphicRef86770 \" href=\"UTD.htm?5/43/5822\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/67\">",
"     67",
"    </a>",
"    ]. They suggested that assessment with ambulatory monitoring and exercise testing should be performed in patients with persistent preexcitation based on electrocardiographic evaluation. If there is persistent excitation or uncertain loss of preexcitation on these studies, they suggested transesophageal or invasive EPS with possible ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We evaluate children with WPW syndrome who are asymptomatic with noninvasive risk stratification via Holter monitor and exercise testing. Those with persistent preexcitation are considered to be at increased risk. Such patients over the age of five years are offered EPS and possible radiofrequency ablation. Patients under the age of five years do not undergo routine EP testing, because of the increased risk of complications and because preexcitation in infants often disappears at least transiently as they get older. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Complications'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H16#H16\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62714099\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality is greater in patients with SVT and structural heart disease compared with patients without comorbid cardiovascular disease. This was illustrated in a study that identified 1755 hospitalized cases of patients less than 25 years of age with a discharge diagnosis of SVT from the Pediatric Health Information System database between 2003 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/9/15514/abstract/68\">",
"     68",
"    </a>",
"    ]. In this cohort, 52 percent of patients had comorbid structural heart disease, and there were 68 deaths. Mortality was 6 percent in patients with structural heart disease and 1 percent in those without structural heart disease. Multivariate regression analysis showed increased mortality in patients with structural heart disease, less than one month of age, and with cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment strategy for SVT depends upon the patient's presentation and clinical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infant or child who presents in the nursery or to the emergency department in SVT should have a 15-lead ECG performed while a hemodynamic assessment is made. If the child is hemodynamically unstable, synchronized DC cardioversion with 0.5",
"    <span class=\"nowrap\">",
"     J/kg",
"    </span>",
"    should be performed. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cardioversion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the child is hemodynamically stable, vagal maneuvers should be attempted to terminate the tachycardia (",
"    <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"     table 1",
"    </a>",
"    ). For an infant, this consists of the application of an ice bag to the face for 15 to 30 seconds. In an older child, the vagal maneuver should consist of bearing down (Valsalva maneuver) for 15 to 20 seconds. A continuous ECG rhythm strip should be obtained during the maneuver.",
"   </p>",
"   <p>",
"    If the vagal maneuver does not convert SVT to normal rhythm, an intravenous catheter should be placed.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     Adenosine",
"    </a>",
"    should be administered in an initial bolus dose of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    followed by a rapid saline flush. If the rhythm does not convert with the initial dose, adenosine is repeated with increases to a maximum dose of 0.25 to 0.35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or a total dose of 12 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the acute episode is terminated, a 12-lead ECG and echocardiogram should be performed to look for evidence of WPW syndrome and structural heart disease. If this is the first episode of SVT and there is no evidence of ventricular dysfunction and no hemodynamic instability, we offer the parents the option of expectant management with no specific treatment. We monitor the child for at least 24 hours and teach the parents how to check the heart rate. The parents (and child, if able) are taught vagal maneuvers (such as ice bag or Valsalva) to assist in self-termination of SVT if it recurs.",
"   </p>",
"   <p>",
"    If the child has frequent episodes of tachycardia or is symptomatic, we initiate drug therapy. Our first-line regimen in infants is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    (2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into four doses). In older children we use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"     atenolol",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), a longer acting beta blocker. We do",
"    <strong>",
"     not",
"    </strong>",
"    treat patients with WPW syndrome with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    or calcium channel blockers.",
"   </p>",
"   <p>",
"    If the child is older than five years and weighs more than 15 kg, we offer the family the option of RFA rather than drug therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef51645 \" href=\"UTD.htm?11/18/11567\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Wolff-Parkinson-White (WPW) syndrome without symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;We evaluate children with WPW syndrome who are asymptomatic with noninvasive risk stratification via Holter monitor and exercise testing (",
"    <a class=\"graphic graphic_algorithm graphicRef86770 \" href=\"UTD.htm?5/43/5822\">",
"     algorithm 3",
"    </a>",
"    ). Those with persistent preexcitation are considered to be at high risk and should undergo further evaluation with an electrophysiology study and possible ablation therapy. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Asymptomatic Wolff-Parkinson-White (WPW) syndrome'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/1\">",
"      Josephson ME, Wellens HJ. Differential diagnosis of supraventricular tachycardia. Cardiol Clin 1990; 8:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/2\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/3\">",
"      Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. J Pediatr 1996; 129:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/4\">",
"      Atkins DL, Kerber RE. Pediatric defibrillation: current flow is improved by using \"adult\" electrode paddles. Pediatrics 1994; 94:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/5\">",
"      Rodriguez E, Jordan R. Contemporary trends in pediatric sedation and analgesia. Emerg Med Clin North Am 2002; 20:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/6\">",
"      Guidelines for the elective use of conscious sedation, deep sedation, and general anesthesia in pediatric patients. Committee on Drugs. Section on anesthesiology. Pediatrics 1985; 76:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/7\">",
"      Bisset GS 3rd, Gaum W, Kaplan S. The ice bag: a new technique for interruption of supraventricular tachycardia. J Pediatr 1980; 97:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/8\">",
"      Garson A Jr, Gillette PC, McNamara DG. Supraventricular tachycardia in children: clinical features, response to treatment, and long-term follow-up in 217 patients. J Pediatr 1981; 98:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/9\">",
"      M&uuml;ller G, Deal BJ, Benson DW Jr. \"Vagal maneuvers\" and adenosine for termination of atrioventricular reentrant tachycardia. Am J Cardiol 1994; 74:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/10\">",
"      Overholt ED, Rheuban KS, Gutgesell HP, et al. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988; 61:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/11\">",
"      Paul T, Bertram H, B&ouml;kenkamp R, Hausdorf G. Supraventricular tachycardia in infants, children and adolescents: diagnosis, and pharmacological and interventional therapy. Paediatr Drugs 2000; 2:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/12\">",
"      Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. N Engl J Med 1991; 325:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/13\">",
"      Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol 1992; 69:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/14\">",
"      Tanel RE, Walsh EP, Triedman JK, et al. Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients. J Pediatr 1997; 131:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/15\">",
"      Sherwood MC, Lau KC, Sholler GF. Adenosine in the management of supraventricular tachycardia in children. J Paediatr Child Health 1998; 34:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/16\">",
"      Willerson JT. July 4, 2000. Circulation 2000; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/17\">",
"      Crosson JE, Etheridge SP, Milstein S, et al. Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children. Am J Cardiol 1994; 74:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/18\">",
"      Losek JD, Endom E, Dietrich A, et al. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med 1999; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/19\">",
"      Till J, Shinebourne EA, Rigby ML, et al. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J 1989; 62:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/20\">",
"      Lenk M, Celiker A, Alehan D, et al. Role of adenosine in the diagnosis and treatment of tachyarrhythmias in pediatric patients. Acta Paediatr Jpn 1997; 39:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/21\">",
"      Strickberger SA, Man KC, Daoud EG, et al. Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med 1997; 127:417.",
"     </a>",
"    </li>",
"    <li>",
"     Adenocard IV prescribing information. Astellas Pharma US, INc., February 2011. adenocard.com (Accessed on August 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/23\">",
"      DeGroff CG, Silka MJ. Bronchospasm after intravenous administration of adenosine in a patient with asthma. J Pediatr 1994; 125:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/24\">",
"      Bennett-Guerrero E, Young CC. Bronchospasm after intravenous adenosine administration. Anesth Analg 1994; 79:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/25\">",
"      Epstein ML, Kiel EA, Victorica BE. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pediatrics 1985; 75:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/26\">",
"      Garson A Jr. Medicolegal problems in the management of cardiac arrhythmias in children. Pediatrics 1987; 79:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/27\">",
"      Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med 1986; 104:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/28\">",
"      Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997; 127:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/29\">",
"      Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/30\">",
"      Soult JA, Mu&ntilde;oz M, Lopez JD, et al. Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children. Pediatr Cardiol 1995; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/31\">",
"      Drago F, Mazza A, Guccione P, et al. Amiodarone used alone or in combination with propranolol: a very effective therapy for tachyarrhythmias in infants and children. Pediatr Cardiol 1998; 19:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/32\">",
"      Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/33\">",
"      Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol 1994; 74:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/34\">",
"      Volkmann H, Dannberg G, Heinke M, K&uuml;hnert H. Termination of tachycardias by transesophageal electrical pacing. Pacing Clin Electrophysiol 1992; 15:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/35\">",
"      Gilljam T, Jaeggi E, Gow RM. Neonatal supraventricular tachycardia: outcomes over a 27-year period at a single institution. Acta Paediatr 2008; 97:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/36\">",
"      Seslar SP, Garrison MM, Larison C, Salerno JC. A multi-institutional analysis of inpatient treatment for supraventricular tachycardia in newborns and infants. Pediatr Cardiol 2013; 34:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/37\">",
"      Benson DW Jr, Dunnigan A, Benditt DG, et al. Prediction of digoxin treatment failure in infants with supraventricular tachycardia: role of transesophageal pacing. Pediatrics 1985; 75:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/38\">",
"      O'Sullivan JJ, Gardiner HM, Wren C. Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? J Am Coll Cardiol 1995; 26:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/39\">",
"      Franklin WH, Deal BJ, Strasburger JF, et al. Do infants have medically refractory supraventricular tachycardia? (abstract). J Am Coll Cardiol 1994; 23:250A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/40\">",
"      Benson DW Jr, Dunnigan A, Green TP, et al. Periodic procainamide for paroxysmal tachycardia. Circulation 1985; 72:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/41\">",
"      Margolis B, DeSilva RA, Lown B. Episodic drug treatment in the management of paroxysmal arrhythmias. Am J Cardiol 1980; 45:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/42\">",
"      Sanatani S, Hamilton RM, Gross GJ. Predictors of refractory tachycardia in infants with supraventricular tachycardia. Pediatr Cardiol 2002; 23:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/43\">",
"      Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977; 56:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/44\">",
"      Weindling SN, Saul JP, Walsh EP. Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants. Am Heart J 1996; 131:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/45\">",
"      Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circ Arrhythm Electrophysiol 2012; 5:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/46\">",
"      Pongiglione G, Strasburger JF, Deal BJ, Benson DW Jr. Use of amiodarone for short-term and adjuvant therapy in young patients. Am J Cardiol 1991; 68:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/47\">",
"      Etheridge SP, Craig JE, Compton SJ. Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants. Am Heart J 2001; 141:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/48\">",
"      Fenrich AL Jr, Perry JC, Friedman RA. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. J Am Coll Cardiol 1995; 25:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/49\">",
"      Price JF, Kertesz NJ, Snyder CS, et al. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children &lt;1 year of age. J Am Coll Cardiol 2002; 39:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/50\">",
"      Knudson JD, Cannon BC, Kim JJ, Moffett BS. High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol 2011; 32:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/51\">",
"      Van Hare GF, Lesh MD, Scheinman M, Langberg JJ. Percutaneous radiofrequency catheter ablation for supraventricular arrhythmias in children. J Am Coll Cardiol 1991; 17:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/52\">",
"      Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med 1982; 306:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/53\">",
"      Huang SK, Graham AR, Lee MA, et al. Comparison of catheter ablation using radiofrequency versus direct current energy: biophysical, electrophysiologic and pathologic observations. J Am Coll Cardiol 1991; 18:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/54\">",
"      Friedman RA, Walsh EP, Silka MJ, et al. NASPE Expert Consensus Conference: Radiofrequency catheter ablation in children with and without congenital heart disease. Report of the writing committee. North American Society of Pacing and Electrophysiology. Pacing Clin Electrophysiol 2002; 25:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/55\">",
"      Van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol 2004; 15:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/56\">",
"      Kugler JD, Danford DA, Houston K, Felix G. Radiofrequency catheter ablation for paroxysmal supraventricular tachycardia in children and adolescents without structural heart disease. Pediatric EP Society, Radiofrequency Catheter Ablation Registry. Am J Cardiol 1997; 80:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/57\">",
"      Kugler JD, Danford DA, Deal BJ, et al. Radiofrequency catheter ablation for tachyarrhythmias in children and adolescents. The Pediatric Electrophysiology Society. N Engl J Med 1994; 330:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/58\">",
"      Kugler JD. Radiofrequency catheter ablation for supraventricular tachycardia. Should it be used in infants and small children? Circulation 1994; 90:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/59\">",
"      Miyazaki A, Blaufox AD, Fairbrother DL, Saul JP. Cryo-ablation for septal tachycardia substrates in pediatric patients: mid-term results. J Am Coll Cardiol 2005; 45:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/60\">",
"      Collins KK, Dubin AM, Chiesa NA, et al. Cryoablation versus radiofrequency ablation for treatment of pediatric atrioventricular nodal reentrant tachycardia: initial experience with 4-mm cryocatheter. Heart Rhythm 2006; 3:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/61\">",
"      LaPage MJ, Saul JP, Reed JH. Long-term outcomes for cryoablation of pediatric patients with atrioventricular nodal reentrant tachycardia. Am J Cardiol 2010; 105:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/62\">",
"      Crawford FA Jr, Gillette PC. Surgical treatment of cardiac dysrhythmias in infants and children. Ann Thorac Surg 1994; 58:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/63\">",
"      Lazorishinets VV, Glagola MD, Stychinsky AS, et al. Surgical treatment of Wolf-Parkinson-White syndrome during plastic operations in patients with Ebstein's anomaly. Eur J Cardiothorac Surg 2000; 18:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/64\">",
"      Mavroudis C, Deal BJ, Backer CL, Tsao S. Arrhythmia surgery in patients with and without congenital heart disease. Ann Thorac Surg 2008; 86:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/65\">",
"      Santinelli V, Radinovic A, Manguso F, et al. The natural history of asymptomatic ventricular pre-excitation a long-term prospective follow-up study of 184 asymptomatic children. J Am Coll Cardiol 2009; 53:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/66\">",
"      Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1996; 27:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/67\">",
"      Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American College of Cardiology Foundation (ACCF), et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 2012; 9:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/9/15514/abstract/68\">",
"      Salerno JC, Garrison MM, Larison C, Seslar SP. Case fatality in children with supraventricular tachycardia in the United States. Pacing Clin Electrophysiol 2011; 34:832.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5782 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15514=[""].join("\n");
var outline_f15_9_15514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hemodynamic assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemodynamically unstable",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adenosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Verapamil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Procainamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transesophageal pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CHRONIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - First-line agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cryoablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ASYMPTOMATIC WOLFF-PARKINSON-WHITE (WPW) SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62714099\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Wolff-Parkinson-White (WPW) syndrome without symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5782\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5782|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 1\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/18/11567\" title=\"algorithm 2\">",
"      Chronic SVT management children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/43/5822\" title=\"algorithm 3\">",
"      PACES HRS - Treatment asymptomatic pediatric WPW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5782|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/42/22189\" title=\"table 1\">",
"      Pediatric supraventricular tachycardia rapid overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5782|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/50/41775\" title=\"waveform 1\">",
"      ECG changes in paroxysmal SVT after administration of adenosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/55/35706\" title=\"waveform 2\">",
"      ECG WPW tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9832?source=related_link\">",
"      Approach to the child with tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_9_15515="Immunostimulating herbs";
var content_f15_9_15515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunostimulating herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boneset",
"       </td>",
"       <td>",
"        Stimulant in vitro",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calendula",
"       </td>",
"       <td>",
"        Stimulant in vitro",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drosera",
"       </td>",
"       <td>",
"        Stimulant and depressant (in vitro)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinacea",
"       </td>",
"       <td>",
"        Stimulant in vitro, in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginseng, eleutherococcus",
"       </td>",
"       <td>",
"        Stimulant, animal, human",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mistletoe",
"       </td>",
"       <td>",
"        Stimulant, animal, human; suppressant (high doses), human",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saw palmetto",
"       </td>",
"       <td>",
"        Stimulant in vivo",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.284.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15515=[""].join("\n");
var outline_f15_9_15515=null;
var title_f15_9_15516="Childhood features of SFTPC and ABCA3";
var content_f15_9_15516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of children with SFTPC and ABCA3 mutations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        SFTPC",
"        <sup>",
"         [1,2]",
"        </sup>",
"        <br/>",
"        (n = 29)",
"       </td>",
"       <td class=\"subtitle1\">",
"        ABCA3",
"        <sup>",
"         [3]",
"        </sup>",
"        <br/>",
"        (n = 9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tachypnea",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to thrive",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crackles",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clubbing",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pectus excavatum",
"       </td>",
"       <td class=\"centered\">",
"        NS",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical features observed in children with SFTPC and ABCA3 related lung disease who presented after the neonatal period. (+ indicates that up to 1/3 of patients exhibited the finding, ++ indicates that up to 2/3 exhibited the finding, +++ indicates that more than 2/3 exhibited the finding.)",
"    <div class=\"footnotes\">",
"     SFTPC: surfactant protein C; ABCA3: member A3 of the ATP Binding Cassette family of proteins; NS: not specified.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Abou Taam R, Jaubert F, Emond S, et al. Familial interstitial disease with I73T mutation: A mid- and long-term study. Pediatr Pulmonol 2009; 44:167.",
"       </li>",
"       <li>",
"        Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95:449.",
"       </li>",
"       <li>",
"        Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63:366.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15516=[""].join("\n");
var outline_f15_9_15516=null;
var title_f15_9_15517="Digoxin in HF";
var content_f15_9_15517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digoxin withdrawal worsens HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Probability of worsening heart failure in stable patients treated with digoxin, diuretics, and angiotensin converting enzyme inhibitors in patients switched to placebo (upper line) or continued on digoxin (lower line). Patients withdrawn from digoxin fared much worse, with the difference increasing with time (p",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Packer, M, Gheorghiade, M, Young, JB, et al, N Engl J Med 1993; 329:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15517=[""].join("\n");
var outline_f15_9_15517=null;
var title_f15_9_15518="Contents: Pediatric ophthalmology";
var content_f15_9_15518=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric ophthalmology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric ophthalmology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Conjunctiva; episclera and sclera",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20760\">",
"           Conjunctivitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/23/5496\">",
"           Approach to the child with leukocoria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/59/24505\">",
"           Visual development and vision assessment in infants and children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eye trauma and ocular emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7718\">",
"           Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20602\">",
"           Child abuse: Eye findings in children with abusive head trauma (AHT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34600\">",
"           Corneal abrasions and corneal foreign bodies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eyelids",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19048\">",
"           Blepharitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glaucoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41463\">",
"           Overview of glaucoma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/57/5016\">",
"           Primary infantile glaucoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lacrimal system",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7079\">",
"           Approach to the child with persistent tearing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29350\">",
"           Nasolacrimal duct obstruction (dacryostenosis) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lens",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22761\">",
"           Cataract in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/37/41557\">",
"           Ectopia lentis (dislocated lens) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuro-ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6906\">",
"           Congenital anomalies and acquired abnormalities of the optic nerve",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/44/12999\">",
"           Fourth cranial nerve (trochlear nerve) palsy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/32/32262\">",
"           Horner's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/15/20726\">",
"           Myopathies affecting the extraocular muscles in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9464\">",
"           Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29944\">",
"           Optic neuritis: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1034\">",
"           Pendular nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/2/43046\">",
"           Sixth cranial nerve (abducens nerve) palsy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/8/28806\">",
"           Supranuclear disorders of gaze in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/34/40487\">",
"           Third cranial nerve (oculomotor nerve) palsy in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Premature infant",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10762\">",
"           Retinopathy of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Strabismus and amblyopia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41800\">",
"           Causes of horizontal strabismus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26790\">",
"           Causes of vertical strabismus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/8/34951\">",
"           Evaluation and management of strabismus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/61/8153\">",
"           Overview of amblyopia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28628\">",
"           Refractive errors in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/24/27018\">",
"           Overview of retinoblastoma",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-FE6D573745-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_9_15518=[""].join("\n");
var outline_f15_9_15518=null;
var title_f15_9_15519="Choledochal cyst type 1-C";
var content_f15_9_15519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choledochal cyst type 1-C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Choledochal cyst type 1-C with cystolithiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright &copy; 1997 Taylor and Francis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_9_15519=[""].join("\n");
var outline_f15_9_15519=null;
